WO2017050218A1 - Salts and solid forms of monobactam antibiotic - Google Patents

Salts and solid forms of monobactam antibiotic Download PDF

Info

Publication number
WO2017050218A1
WO2017050218A1 PCT/CN2016/099482 CN2016099482W WO2017050218A1 WO 2017050218 A1 WO2017050218 A1 WO 2017050218A1 CN 2016099482 W CN2016099482 W CN 2016099482W WO 2017050218 A1 WO2017050218 A1 WO 2017050218A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
oxo
methyl
oxooxazolidin
ethylidene
Prior art date
Application number
PCT/CN2016/099482
Other languages
French (fr)
Inventor
Eric Aubin
Anthony Casarez
Andreas Fisch
Zaixing LI
Mika Lindvall
Heinz Ernst Moser
Michael Mutz
Folkert Reck
Bernd Ulrich Riebesehl
Marc SCHOENHENTZ
Vijay SETHURAMAN
Robert Lowell Simmons
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2018003592A priority Critical patent/MX2018003592A/en
Priority to SI201630906T priority patent/SI3353175T1/en
Priority to RU2018114480A priority patent/RU2754180C2/en
Priority to MA42946A priority patent/MA42946B1/en
Priority to ES16848099T priority patent/ES2817537T3/en
Priority to EA201890771A priority patent/EA037569B1/en
Priority to US15/762,724 priority patent/US10919887B2/en
Priority to KR1020187011354A priority patent/KR20180054816A/en
Priority to EP16848099.4A priority patent/EP3353175B1/en
Priority to CA2999794A priority patent/CA2999794C/en
Priority to JP2018515607A priority patent/JP6837480B2/en
Priority to DK16848099.4T priority patent/DK3353175T3/en
Priority to LTEP16848099.4T priority patent/LT3353175T/en
Priority to CN201680055680.4A priority patent/CN108137573B/en
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to AU2016327264A priority patent/AU2016327264B2/en
Priority to BR112018005805-0A priority patent/BR112018005805B1/en
Priority to RS20201038A priority patent/RS60805B1/en
Publication of WO2017050218A1 publication Critical patent/WO2017050218A1/en
Priority to IL258254A priority patent/IL258254B/en
Priority to PH12018500653A priority patent/PH12018500653A1/en
Priority to HK18116415.3A priority patent/HK1257271A1/en
Priority to HRP20201423TT priority patent/HRP20201423T1/en
Priority to CY20201100840T priority patent/CY1123509T1/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to salts and crystal forms of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid that are suitable for commercial scale production, as well as pharmaceutical compositions containing these materials, methods of preparing them, and their use in therapy.
  • nosocomial infections Over the past several decades, the frequency of antimicrobial resistance and its association with serious infectious diseases have increased at alarming rates. The increasing prevalence of resistance among nosocomial pathogens is particularly disconcerting. Of the over 2 million nosocomial (hospital-acquired) infections occurring each year in the United States, 50 to 60%are caused by antimicrobial-resistant strains of bacteria. The high rate of resistance to commonly used antibacterial agents increases the morbidity, mortality, and costs associated with nosocomial infections. In the United States, nosocomial infections are thought to contribute to or cause more than 77,000 deaths per year and cost approximately $5 to $10 billion annually.
  • Important causes of Gram-negative resistance include extended-spectrum ⁇ -lactamases (ESBLs) , serine carbapenemases (KPCs) and metallo- ⁇ -lactamases (for example NDM-1) in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis, high-level third-generation cephalosporin (AmpC) ⁇ -lactamase resistance among Enterobacter species and Citrobacter freundii, and multidrug-resistance genes observed in Pseudomonas, Acinetobacter, and Stenotrophomonas.
  • the problem of antibacterial resistance is compounded by the existence of bacterial strains resistant to multiple antibacterials. For example, Klebsiella pneumonia harboring NDM-1 metallo- ⁇ -lactamase carries frequently additional serine- ⁇ -lactamases on the same plasmid that carries the NDM-1.
  • the current invention provides solid forms of such compounds that are especially well suited for commercial-scale production due to their handling properties under convenient operating conditions for manufacture.
  • Compound X and many of its salts are solid at room temperature, and can be produced in various solid forms, depending on the conditions used to produce, purify or crystallize the material.
  • the existence of multiple solid forms, often referred to as polymorphs, is well known for solid pharmaceutical compounds, and the chemical and physical stability as well as handling properties of such compounds often depend on which solid form is used.
  • the selection of a particular solid form of the active drug substance is often very important in the design of a reliable and reproducible production process, and in storage, handling and distribution of a safe and effective form of the drug substance.
  • the present inventors have discovered certain salts and polymorph forms of Compound X that are particularly suitable for use in the manufacture, storage or administration of Compound X as described herein.
  • Compound X in solution is preferably used and stored at a pH between 4 and 6, preferably between 4.0 and 5.5, for maximum stability in the presence of moisture.
  • Optimal solution stability is achieved at a pH of about 4.0 to 5.5
  • the invention provides pharmaceutical compositions comprising Compound X at a pH between 4 and 6, preferably between 4.0 and 5.5, and more preferably at a pH of about 5 ⁇ 0.5 or at pH of 5 ⁇ 0.2.
  • Suitable compositions comprise Compound X in an aqueous solution, such as a dextrose or saline solution, which may be isotonic, and may contain other substances such as stabilizers, antioxidants, buffers or pH modifiers, nutrients, and the like.
  • the desired pH is achieved by combining Compound X and a pH modifier suitable to achieve the desired pH in an aqueous solution.
  • Suitable pH modifiers include but are not limited to sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium hydroxide, amines such as TRIS (tris (hydroxymethyl) aminomethane) , and amino acids such as arginine, lysine, histidine, and the like.
  • Known monobactams, including aztreonam have been formulated with arginine.
  • Suitable pH can be achieved by adding a pH modifier to an aqueous solution of Compound X, or by adding Compound X to an aqueous solution containing the pH modifier.
  • Appropriate quantities of the pH modifier and Compound X can be readily determined by the skilled person.
  • Suitable pH modifiers include sodium hydroxide and arginine.
  • a solution or suspension of Compound X can be treated with sodium hydroxide, or with arginine, to produce a solution comprising a sodium salt or an arginine salt of the Compound.
  • this solution can be lyophilized to remove the water and any co-solvents present, leaving a lyophilized solid that comprises Compound X along with the pH modifier, or a salt formed by Compound X and the pH modifier, e.g., the sodium salt or arginine salt of Compound X.
  • An arginine salt of 1- ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid.
  • the salt is an (L) -arginine salt.
  • a pharmaceutical composition comprising a compound according to any one of embodiments 1-4 and at least one pharmaceutically acceptable carrier or excipient.
  • Form 9 A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 9) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ) : 6.3, 12.6, and 22.3; and optionally by one or more additional peaks selected from 22.1, 23.1, 27.0 and 27.5. In some embodiments, Form 9 has additional XRPD peaks as described below.
  • Form 10 A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 10) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ) : 6.6, 11.0, and 16.5; and optionally by one or more additional peaks selected from 22.2 and 23.4. In some embodiments, Form 10 has additional XRPD peaks as described below.
  • Form 11 A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 11) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ) : 7.4, 9.7, and 29.3; and optionally by one or more additional peaks selected from peaks at 17.0, 19.5, 22.2, 26.3 and 28.1. In some embodiments, Form 11 has additional XRPD peaks as described below.
  • Form 12 A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 12) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ) : 19.0, 20.4, and 24.0; and optionally by one or more additional peaks selected from peaks at 7.3, 24.7, and 27.2. In some embodiments, Form 12 has additional XRPD peaks as described below.
  • a pharmaceutical composition comprising 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid and arginine.
  • composition of claim 19 which further comprises a pharmaceutically acceptable carrier.
  • composition of claim 20 wherein the carrier is aqueous.
  • composition of claim 21 which is at a pH of about 5.0.
  • the bacterium causing the Gram-negative bacterial infection is selected from Citrobacter, Enterobacter, Eschirichia, Haemophilus, Klebsiella, Morganella, Moraxella, Pseudomonas, Proteus, Salmonella, Serratia, Shigella, and Neisseria bacteria.
  • the bacterium causing the Gram-negative bacterial infection is a species selected from Citrobacter, Enterobacter, Eschirichia, Haemophilus, Klebsiella, Morganella, Moraxella, Pseudomonas, Proteus, Salmonella, Serratia, Shigella, and Neisseria bacteria.
  • a method of treatment for a Gram-negative infection comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 4, or a crystalline form according to any one of claims 7 to 18, or a pharmaceutical composition according to any one of claims 19-23.
  • the bacterium causing the Gram-negative bacterial infection is a species selected from Citrobacter, Enterobacter, Eschirichia, Haemophilus, Klebsiella, Morganella, Moraxella, Pseudomonas, Proteus, Salmonella, Serratia, Shigella, or Neisseria bacteria.
  • the invention provides a crystalline form of Compound X (Form 1) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ) : 6.6, 13.4, and 18.8.
  • Form 1 exhibits at least the following characteristic X-ray powder diffraction peaks: 6.6, 13.4, 16.6, 17.9, 18.8, 20.3, 25.1, and 28.9.
  • Form 1 exhibits at least the characteristic X-ray powder diffraction peaks shown in List 1, or any subset of at least five peaks selected from List 1.
  • Form 1 exhibits an X-ray powder diffraction pattern substantially the same as that shown in Figure 1.
  • the invention provides a crystalline form of Compound X (Form 2) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ) : 7.5, 19.3 and 20.0.
  • Form 2 exhibits at least the following characteristic X-ray powder diffraction peaks: 6.7, 7.5, 13.3, 13.7, 15.3, 17.9, 18.7, 19.3 and 20.0.
  • Form 2 exhibits at least the characteristic X-ray powder diffraction peaks shown in List 2, or any subset of at least five peaks selected from List 2.
  • Form 2 exhibits an X-ray powder diffraction pattern substantially the same as that shown in Figure 2.
  • the invention provides a crystalline form of Compound X (Form 3) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ) : 7.3, 18.9, and 21.2; and optionally further including a peak at 8.3.
  • Form 3 exhibits at least the following characteristic X-ray powder diffraction peaks: 7.3, 13.9, 16.7, 18.9, 20.3, 21.2, and 24.6.
  • Form 3 exhibits at least the characteristic X-ray powder diffraction peaks shown in List 3, or any subset of at least five peaks selected from List 3.
  • Form C exhibits an X-ray powder diffraction pattern substantially the same as that shown in Figure 4.
  • the invention provides a crystalline form of Compound X (Form 4) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ) : 7.0, 8.6, 19.3 and 20.9.
  • Form 4 exhibits at least the following characteristic X-ray powder diffraction peaks: 7.0, 8.6, 15.2, 17.0, 18.0, 19.3, 20.9, 24.5, and 26.9.
  • Form 4 exhibits at least the characteristic X-ray powder diffraction peaks shown in List 4, or any subset of at least five peaks selected from List 4.
  • Form 4 exhibits an X-ray powder diffraction pattern substantially the same as that shown in Figure 5.
  • the invention provides a crystalline form of Compound X (Form 5) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ) : 7.3, 9.3, and 27.8; and optionally further including a peak at 19.9.
  • Form 5 exhibits at least the following characteristic X-ray powder diffraction peaks: 7.3, 9.3, 16.3, 18.6, 19.2, 19.9, 21.7, 24.1, 24.9, 27.3, 27.8 and 29.8.
  • Form 5 exhibits at least the characteristic X-ray powder diffraction peaks shown in List 5, or any subset of at least five peaks selected from List 5.
  • Form 5 exhibits an X-ray powder diffraction pattern substantially the same as that shown in Figure 6.
  • the invention provides a crystalline form of Compound X (Form 6) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ) : 8.1, 9.2, 12.8, 21.2, and 24.7.
  • Form 6 exhibits at least the following characteristic X-ray powder diffraction peaks: 8.1, 9.2, 12.8, 13.9, 14.4, 16.7, 20.1, 21.2, 24.7, and 26.6.
  • Form 6 exhibits at least the characteristic X-ray powder diffraction peaks shown in List 6, or any subset of at least five peaks selected from List 6.
  • Form 6 exhibits an X-ray powder diffraction pattern substantially the same as that shown in Figure 7.
  • the invention provides a crystalline form of Compound X (Form 7) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ) : 6.7, 7.3 and 20.3.
  • Form 7 exhibits at least the following characteristic X-ray powder diffraction peaks: 6.7, 7.3, 17.6, 18.0, 20.3, and 24.9.
  • Form 7 exhibits at least the characteristic X-ray powder diffraction peaks shown in List 7, or any subset of at least five peaks selected from List 7.
  • Form 7 exhibits an X-ray powder diffraction pattern substantially the same as that shown in Figure 8.
  • the invention provides a crystalline form of Compound X (Form 8) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ) : 6.2, 21.8, and 25.9.
  • Form 8 exhibits at least the following characteristic X-ray powder diffraction peaks: 6.2, 17.8, 20.7, 21.8, and 25.9.
  • Form 8 exhibits at least the characteristic X-ray powder diffraction peaks shown in List 8, or any subset of at least five peaks selected from List 8.
  • Form 8 exhibits an X-ray powder diffraction pattern substantially the same as that shown in Figure 9.
  • the polymorphs of the invention have crystalline properties and are preferably at least 50%crystalline, more preferably at least 60%crystalline, still more preferably at least 70%crystalline and most preferably at least 80%crystalline. Crystallinity can be estimated by conventional X-ray diffractometry techniques or by infra-red spectroscopic techniques.
  • the solid form of Compound X comprises one or more of the Forms described herein.
  • a solid form of Compound X can include two or more of these Forms, i.e., it can be a mixture of two or more Forms.
  • a sample of the solid form mainly consists of a single Form selected from Forms 1-8, meaning that 50%or more of the material is of one solid Form. Relative amounts of various Forms in a mixture can be determined from XRPD data. As described herein, some of the Forms can evolve or interconvert under suitable conditions, such as Forms 4 and 5, which can occur as a mixture, and can interconvert depending on the relative humidity and temperature at which the material is maintained.
  • the polymorphs of the invention are from 50%, 60%, 70%, 80%or 90%to 95%, 96%, 97%, 98%, 99%or 100%crystalline.
  • X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ) are measured using copper X-rays with a wavelength of (alpha1) and (alpha2) . Peak locations are reported in degrees 2 ⁇ and are understood to be subject to small numerical variations and it should thus be understood that the angles are subject to variation of ⁇ 0.2°.
  • the crystalline forms of the present invention can exist in either unsolvated or solvated forms.
  • the term 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and an amount of one or more pharmaceutically acceptable solvents.
  • pharmaceutically acceptable solvents include ethanol and water.
  • Several polymorphs of Compound X as described herein are hydrates.
  • the invention provides a salt or crystalline form defined herein for use in therapy.
  • the invention provides a method of treatment by therapy, comprising administering to a subject in need thereof a pharmaceutically acceptable amount of a salt or crystalline form according to the invention.
  • the invention provides the use of a salt or crystalline form defined herein in the manufacture of a medicament for use in therapy.
  • the therapy is the treatment of an infection caused by a Gram-negative bacterium.
  • the invention also provides processes for the preparation of the crystalline forms described herein.
  • the invention provides a process for the preparation of any of Forms 1, 2, 3, 4, 5, 6, 7, and 8 as described herein comprising the crystallisation of the desired Form from a solution of Compound X, using solvent systems and conditions described in the Examples provided herein.
  • references herein to “treatment” include references to curative, palliative and prophylactic treatment, unless there are specific indications to the contrary.
  • the terms “therapy, “therapeutic” and “therapeutically” should be construed in the same way.
  • Compound X is typically administered by injection or infusion, and may be prepared for administration by dissolving Compound X in a suitable amount of water or of an aqueous solution such as dextrose or saline, e.g., isotonic dextrose or saline.
  • aqueous solution such as dextrose or saline, e.g., isotonic dextrose or saline.
  • the formulated composition may also include a pH modifier such as sodium hydroxide, sodium bicarbonate, sodium carbonate, potassium hydroxide, potassium carbonate, calcium hydroxide, magnesium hydroxide, meglumine, TRIS, or an amino acid (e.g., lysine, histidine, or arginine) in quantity sufficient to provide a desired pH, such as a pH between 4 and 6. While the amino acids used in the examples were (L) -amino acids, a (D) -amino acid or racemic mixture could be used instead.
  • a pH modifier such as sodium hydroxide, sodium bicarbonate, sodium carbonate, potassium hydroxide, potassium carbonate, calcium hydroxide, magnesium hydroxide, meglumine, TRIS, or an amino acid (e.g., lysine, histidine, or arginine) in quantity sufficient to provide a desired pH, such as a pH between 4 and 6. While the amino acids used in the examples were (L) -amino acids, a (D) -
  • compositions comprising Compound X in solution are typically adjusted to a pH between 4.5 and 5.5, often or at a pH of about 5, such as between pH 4.8 and 5.2.
  • Compound X is formulated with a pH modifier in aqueous solution, and is then lyophilized to a solid form for storage and distribution.
  • aqueous carrier typically a sterile aqueous carrier such as water or an isotonic dextrose or saline solution, or other IV solution such as Ringer’s, Lactated Ringer’s, or Hartmann’s solution.
  • the invention also provides a lyophilizate (asolid prepared by lyophilization) comprising Compound X and a pH modifier such as those mentioned above, e.g.
  • other excipients such as sucrose may be included.
  • a solution of Compound X and arginine (two equivalents) is prepared, and the pH is adjusted to a pH between 4.8 and 5.2 using, for example, sodium hydroxide or hydrochloric acid as needed.
  • the solution is then lyophilized to a white or slightly yellow solid, which is stable for storage and can readily be reconstituted with a suitable sterile aqueous solution for intravenous administration.
  • a solution of Compound X, sucrose, and arginine (two equivalents) in water suitable for injection is prepared, and the pH is adjusted to a pH between 4.8 and 5.2 using, for example, sodium hydroxide or hydrochloric acid as needed.
  • the solution is then lyophilized to a white or slightly yellow solid, which is stable for storage and can readily be reconstituted with a suitable sterile aqueous solution for intravenous administration.
  • the salts and crystalline forms of the present invention may be administered alone or in combination with one or more other drugs. Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients.
  • excipient is used herein to describe any ingredient other than the compound (s) of the invention which may impart either a functional (i.e., drug release rate controlling) and/or a non-functional (i.e., processing aid or diluent) characteristic to the formulations.
  • a functional i.e., drug release rate controlling
  • a non-functional i.e., processing aid or diluent
  • the choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
  • compositions may also comprise a carrier, which is a substantially inert material, often a liquid, used to dilute the active ingredient (s) .
  • a carrier which is a substantially inert material, often a liquid, used to dilute the active ingredient (s) .
  • Suitable carriers are known in the art, and include sterile water and sterile solutions of saline or dextrose, for example.
  • compositions suitable for the delivery of the solid forms of Compound X and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in REMINGTON’S PHARMACEUTICAL SCIENCES, 19th Edition (Mack Publishing Company, 1995) .
  • the total daily dose of the salt or crystalline form is typically in the range 1000 mg to 10,000 mg, or between 2000 mg and 8000 mg, or between 3000 mg and 8000 mg, or between 4000 mg and 6000 mg, depending on the condition of the subject and parameters such as the subject’s body weight, age, and gender.
  • the total daily dose may be administered in a single dose, or it may be divided into two or more doses and may, at the physician's discretion, fall outside of the typical range given herein.
  • the daily dosage would be delivered via intravenous injection or by infusion, and would be administered in one, two, three or four doses, that cumulatively provide the desired total daily dosage.
  • Infusion may be rapid, or it may be performed over a period of between about 15 minutes and 4 hours, commonly over a period of 1-3 hours.
  • a typical dosing schedule would provide three or four infusions daily, each lasting 0.25-2 hours or 0.25-3 hours, delivering 1 to 2 or 1 to 2.5 grams of Compound X per dose, and a typical total daily dose would be 3-8 grams.
  • a dosing schedule may deliver 2 grams of Compound X per infusion, with three one-hour infusions per day.
  • a single infusion of 2-6 grams, or 3-5 grams over 1 or 1.5 or 2 or 2.5 or 3 hours may be used.
  • the above dosages are based on an average human subject having a weight of about 60kg to 70kg, and may be scaled suitably for other subjects.
  • the physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.
  • Figure 1 X-ray powder diffraction pattern of Form 1.
  • Figure 2 X-ray powder diffraction pattern of Form 2.
  • Figure 3 X-ray powder diffraction pattern of Form 1 after stirring with acetone, overlaid by the XRPD for Form 1 for comparison.
  • Figure 4 X-ray powder diffraction pattern of Form 3.
  • Figure 5 X-ray powder diffraction pattern of Form 4.
  • Figure 6A X-ray powder diffraction pattern of Form 5 overlaid on XPRD for Figure 4.
  • Figure 6B X-ray powder diffraction pattern of Form 5 from larger scale preparation.
  • Figure 7 X-ray powder diffraction pattern of Form 6.
  • Figure 8 X-ray powder diffraction pattern of Form 7.
  • Figure 9 X-ray powder diffraction pattern of Form 8.
  • Figure 10 X-ray powder diffraction pattern of Form 9.
  • Figure 11 X-ray powder diffraction pattern of Form 10.
  • Figure 12 X-ray powder diffraction pattern of Form 11.
  • Figure 13 X-ray powder diffraction pattern of Form 12.
  • the sample is then placed in a PANALYTICAL X’PERT PRO MPD diffractometer configured in transmission mode, and analyzed using conditions indicated below.
  • Mass spectra were acquired on LC-MS, SFC-MS, or GC-MS systems using electrospray, chemical and electron impact ionization methods from a range of instruments of the following configurations: Waters ACQUITY UPLC system and equipped with a ZQ 2000 or SQD MS system where (M+1) refers to the protonated molecular ion of the chemical species, (M+) refers to the unprotonated quaternary ammonium cation, (M+Na) refers to the sodium-incorporated ion and (M-1) refers to the deprotonated molecular ion of the chemical species.
  • NMR spectra were run on Bruker AVANCE 500MHz or Varian 400MHz NMR spectrometers using ICON-NMR, under TopSpin program control. Spectra were measured at 298K, unless indicated otherwise, and were referenced relative to the solvent resonance.
  • the starting material for this step can be made using the following approaches or some combination of steps based on these approaches.
  • a protected chiral aldehyde is condensed with 2, 4-dimethoxybenzylamine to make a chiral imine.
  • the chiral aldehyde is known, and can be made from citric acid:
  • the chiral imine can be reacted with protected forms of glycine such as these:
  • the requisite mixed anhydride for the second option can be prepared from CBZ-protected glycine and isopropyl chloroformate in dichloromethane.
  • DMB refers to a 2, 4-dimethoxybenzyl group
  • the dioxolane of this protected intermediate is then hydrolyzed under mild acidic conditions and oxidized to an aldehyde, which can be easily reduced with, e.g. sodium borohydride, to provide the di-protected primary alcohol as shown.
  • the primary alcohol of this intermediate can be converted into a leaving group, for example by treating with iodine and triphenylphosphine to produce a primary iodide, or by treating with a base and a sulfonyl chloride to produce e.g. a mesylate or tosylate.
  • This activated intermediate reacts readily with hydroxyethylamine as shown in step 1 below.
  • Step 1 Benzyl ( (2R, 3S) -1- (2, 4-dimethoxybenzyl) -2- ( ( (2-hydroxyethyl) amino) methyl) -4-oxoazetidin-3-yl) carbamate.
  • Step 2 Benzyl ( (3S, 4R) -1- (2, 4-dimethoxybenzyl) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) azetidin-3-yl) carbamate.
  • benzyl ( (2R, 3S) -1- (2, 4-dimethoxybenzyl) -2- ( ( (2-hydroxyethyl) amino) methyl) -4-oxoazetidin-3-yl) carbamate (4.47g, 10.08 mmol) in chloroform (50 ml) was added carbonyldiimidazole (CDI) (4.90 g, 30.2 mmol) .
  • CDI carbonyldiimidazole
  • Step 3 Benzyl ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) azetidin-3-yl) carbamate. Prepared analogously to a preparation in Mastalerz et al. J. Med. Chem.
  • K 2 S 2 O 8 (663 g, 2.45 mmol) and K 2 HPO 4 (370 mg, 2.13 mmol) were added and the mixture was heated for another 3 h. More K 2 S 2 O 8 (332 mg, 1.23 mmol) and K 2 HPO 4 (185 mg, 1.06 mmol) were added, and it was heated for an additional 2 h, whereupon it was concentrated in vacuo, removing most of the ACN. The mixture was diluted with brine/EtOAc and the layers were separated. The aqueous layer was extracted with EtOAc (3x) and the combined organic layers were dried over Na 2 SO 4 .
  • Step 4 3- ( ( (2R, 3S) -3-amino-4-oxoazetidin-2-yl) methyl) oxazolidin-2-one.
  • Step 1 Benzhydryl 1- ( ( (Z) - (1- (2- ( (tert-butoxycarbonyl) amino) thiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) azetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylate.
  • HATU a variety of other coupling reagents can be used, such as any of the typical carbodiimides, or CDMT (2-chloro-4, 6-dimethoxy-1, 3, 5-triazine) and N-methylmorpholine to form the amide bond generated in Step 1.
  • Step 2 (3S, 4R) -3- ( (Z) -2- ( (1- ( (benzhydryloxy) carbonyl) cyclopropoxy) imino) -2- (2- ( (tert-butoxycarbonyl) amino) thiazol-4-yl) acetamido) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) azetidine-1-sulfonic acid.
  • Step 3 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid.
  • TFA 3.24 mL, 42.0 mmol
  • anisole may be added to the TFA reaction to help reduce by-product formation, which may increase the yield of desired product in this step.
  • the crude residue was purified by reverse phase prep HPLC (XSelect CSH, 30 x 100 mm, 5 ⁇ m, C18 column; ACN-water with 0.1%formic acid modifier, 60 mL/min) , affording the title compound (178 mg, 23%) as a white powder.
  • TGA Pyris 1 TGA, Nitrogen gas (20 mL/min) , scanning at 10°C/min
  • Compound X was prepared as described above and crystallized from solvent to provide materials having the X-ray powder diffraction pattern (XRPD) in Figure 1 or Figure 2. These represent two separate batches of crystalline material, and are referred to herein as Form 1 and Form 2. Forms 1 and 2 have some similar XRPD peaks, and the XRPD for Form 2 shows broadened lines, so the product identified as Form 2 may contain some Form 1 material, or both samples may be mixtures of crystal forms. These two Forms were substantially anhydrous, containing less than about 1%water by weight according to Karl Fischer analysis.
  • Form 1 can also be characterized by a subset of these peaks, for example the peaks at 6.6, 13.4 and 18.8.
  • Form 2 can also be characterized by a subset of these peaks, for example the peaks at 7.5, 19.3 and 20.0.
  • Form 3 Compound X of Form 1 was suspended in methanol and within a few minutes it evolved into a sticky solid product.
  • the product exhibited the XRPD pattern shown in Figure 4, and is referred to herein as Form 3.
  • a different form (Form 8) was obtained after longer stirring in methanol on a larger scale, as described below; thus Form 3 may be a transient form or a mixture formed as Form 1 evolves under these conditions.
  • Form 3 can also be characterized by a subset of these peaks, for example the peaks at 7.3, 18.9 and 21.2.
  • Form 4 Compound X of Form 1 (1.2 g) was suspended in water (12 mL) and stirred at 20°C for 3 days.
  • the product exhibited the XRPD pattern shown in Figure 5, and is referred to herein as Form 4.
  • the XRPD is from a sample dried with filter paper.
  • the TGA analysis for Form 4 shows gradual loss of weight beginning about 40°C and becoming rapid around 100°C, to a plateau at about 60%of original weight at 120-170°C. Above that temperature, a gradual loss of weight is seen.
  • the early loss of mass is consistent with loss of water from Form 4, and with the DSC, which shows a strong endotherm in the same temperature range and a plateau at about 110-180°C.
  • Form 4 shows a rapid loss of about 20%of sample mass as relative humidity dropped to around 50%, after which cycling to lower then higher then lower and then higher relative humidity produced corresponding decrease, increase, decrease and increase of sample mass with a minimum mass about 65%of original, and maximum at about 80%of original mass.
  • Form 4 is thus a hydrated form, and evolves depending on RH.
  • the degree of hydration of the sample varies with relative humidity from an anhydrous form at very low humidity, to a trihydrate at RH about 20-50%, to a hexahydrate at RH above 60%.
  • a sample of Form 4 dried at 0%relative humidity (RH) produces an XRPD consistent with Form 1.
  • Form 4 can also be characterized by a subset of these peaks, for example the peaks at 7.0, 8.6, 19.3 and 20.9.
  • Form 4 A sample of Form 4 was dried under dry air flow for a day, giving a powder that exhibited the XRPD shown in Figure 6A. This material is referred to herein as Form 5.
  • the DSC for Form 5 shows a sharp exotherm at about 204°C, and the sample begins turning black at about this temperature, indicating decomposition.
  • TGA shows about 7%loss of mass between 45 °C and 160°C.
  • Karl Fisher analysis shows a water content of 9.6%for Form 5, corresponding to a trihydrate, but the sample appears to lose mass at RH below about 30%; and at RH above 80%, it converts to Form 4 within a day.
  • Forms 1, 4 and 5 of Compound X thus appear to interconvert as relative humidity is varied, and it may be a mixture of these hydrated forms.
  • Form 5 is a preferred form for handling at ambient temperatures around 25°C during manufacture, because it crystallizes as a well-behaved solid that is more stable during storage and handling than other forms, provided suitable relative humidity of around 20-50%RH, preferably 30-40%, is maintained. Within these RH ranges, the material is primarily trihydrate and is suitably well-behaved and stable for handling and storage without special precautions.
  • the sample produced the XRPD pattern shown in Figure 6B. It appears stable when stored at 25-50%relative humidity, preferably 30-40%RH; at lower or higher relative humidity, it may evolve to different hydrated states as described herein. Over-drying produces a form that decomposed at room temperature within a few hours, further demonstrating the stability advantage of hydrated forms.
  • Form 5 can also be characterized by a subset of these peaks, for example the peaks at 7.3, 9.3, and 27.8; and optionally by peaks at 7.3, 9.3, 19.9 and 27.8.
  • the single crystal structure confirms the presence of three water molecules per molecule of Compound X in the unit cell, with the water molecule located in channels.
  • Form 6 can also be characterized by a subset of these peaks, for example the peaks at 8.1, 9.2, and 12.8; and optionally by additional peaks at 21.2 and 24.7.
  • Form 7 can also be characterized by a subset of these peaks, for example the peaks at 6.7, 7.3 and 20.3.
  • Form 8 can also be characterized by a subset of these peaks, for example the peaks at 6.2, 21.8 and 25.9.
  • Form 9 can be characterized by a subset of these peaks, for example the peaks identified in the table above as ‘strong’ relative intensity, e.g. peaks at 6.3 and 12.6 and optionally one or more of the peaks in the table having medium relative intensity, such as peaks at 22.1, 22.3, 23.1, 27.0 and 27.
  • strong relative intensity e.g. peaks at 6.3 and 12.6
  • medium relative intensity such as peaks at 22.1, 22.3, 23.1, 27.0 and 27.
  • Form 10 can be characterized by the XRPD peaks in the above table having medium to strong relative intensities, e.g. peaks at 6.6, 11.0, 13.3, 15.6, 16.5, 18.6, 22.2, 23.4 and 27.4. It can also be characterized by a subset of these peaks, for example the peaks having relative intensity of 40 or higher, e.g. peaks at 6.6, 11.0, 16.5, 22.2, and 23.4, or by a subset of at least 3 or 4 of these peaks.
  • medium to strong relative intensities e.g. peaks at 6.6, 11.0, 13.3, 15.6, 16.5, 18.6, 22.2, 23.4 and 27.4. It can also be characterized by a subset of these peaks, for example the peaks having relative intensity of 40 or higher, e.g. peaks at 6.6, 11.0, 16.5, 22.2, and 23.4, or by a subset of at least 3 or 4 of these peaks.
  • Compound X of Form 5 the trihydrate, was exposed to relative humidity of 22%for about 3 days to provide a crystalline solid characterized as a dihydrate (Compound X-2H 2 O) based on water content analysis. This material readily reverts to the trihydrate (Form 5) if exposed to relative humidity above about 40%.
  • the dihydrate referred to herein as Form 11, produced the XRPD spectrum shown in Figure 12: the main peaks in that XRPD spectrum are listed in the following table.
  • Form 11 is characterized by the XRPD peaks in this table having relative intensities of 20 or higher, or alternatively those peaks having relative intensity of at least 25, e.g., peaks at 7.4, 9.7, 17.0, 19.5, 22.2, 26.3, 28.1, and 29.3, or a subset of 3, 4 or 5 of these peaks having relative intensity of at least 26 or at least 28 in the table.
  • Compound X of Form 5 was exposed to air with a relative humidity of 65%for about 3 days, providing a crystalline material characterized as a tetra-hydrate based on water content analysis. This material readily reverts to the trihydrate (Form 5) if the relative humidity is reduced to about 40%.
  • the tetrahydrate, referred to herein as Form 12, produced the XRPD spectrum shown in Figure 13: the main peaks in that XRPD spectrum are listed in the following table.
  • Form 12 can be characterized by XRPD peaks having a relative intensity of at least 40 in the table above, i.e. XRPD peaks at 7.3, 17.8, 19.0, 19.8, 20.4, 24.0, 24.7, 24.9, 27.2, 27.8 and 32.1. Alternatively, it can be characterized by a subset of at least 3, or at least 4, or at least 5 of these peaks.
  • Form 12 can also be characterized by the XRPD peaks described as strong relative intensity in the table, i.e., peaks at 7.3, 19.0, 20.4, 24.0, 24.7, and 27.2.
  • Compound X 500 mg
  • L-arginine 332.5 mg
  • Saccharose crystalline, pyrogen-free sucrose: 1000 mg
  • water suitable for injection 8.00 mL
  • the pH of the solution is adjusted, if necessary, using 1.0N HCl or 1.0N NaOH to arrive at a pH of 5.0 ⁇ 0.5, preferably a pH of 5.0 ⁇ 0.2.
  • This provides a solution containing about 62.5 mg/mL of Compound X as an arginine salt.
  • This solution can be filtered if necessary, and can be lyophilized to provide a white or off-white solid (lyophilizate) .
  • the lyophilized solid can be reconstituted with sterile water or a pharmaceutically acceptable aqueous carrier such as isotonic saline or dextrose to provide a solution suitable for intravenous administration.
  • a pharmaceutically acceptable aqueous carrier such as isotonic saline or dextrose
  • the lyophilizate should be stored in a container that excludes light to protect the lyophilizate from photodegradation. This process can be scaled up or down to provide unit dosages for storage and distribution, or bulk material that can be further processed as desired.
  • Compound X in solution should be maintained at a temperature below 10°C, preferably between 0°C and 8°C, and more preferably between 2°C and 8°C, prior to addition of arginine or other base, as the compound is subject to hydrolytic degradation in water in the absence of a base or outside the pH range of 4-6.
  • a mixture according to the above example is prepared as described using the trihydrate (Form 5) of Compound X in an amount that contains about 500 mg of Compound X anhydrous, and is lyophilized in a vial that is then sealed for storage and distribution, preferably using a butyl rubber stopper (e.g., D777 stopper) , where the lyophilizate in each vial contains about 500 mg of Compound X.
  • the vials of lyophilizate are stored at or below room temperature until use.
  • An alternative formulation suitable for IV injection contains Compound X (100 mg) and 0.5N Sodium bicarbonate (0.75 mL) , and pH adjuster if necessary (1 N NaOH or 1 N HCl as needed) to bring the pH to about 5.5 (between pH 5 and pH 6) , plus an amount of water for injection sufficient to achieve a final concentration of 100 mg/ml.
  • Compound X is stable in solid form, but salts of Compound X are more stable in solution than the free acid; thus it became important to identify suitable pharmaceutically acceptable salts to use for administration.
  • Salts of Compound X were prepared by adding a base (1.0 or 2.0 equiv. ) to Compound X in water, and lyophilizing the solution. The solids thus obtained appear to be amorphous by XRPD. In this manner, formation of salts of Compound X were attempted with sodium hydroxide, (L) -lysine, (L) -arginine, calcium hydroxide, meglumine, and magnesium hydroxide.
  • the sodium salts and the arginine salts were found to be particularly stable and thus desirable as forms for administration in aqueous media typically used for intravenous injections and infusions.
  • Samples of the disodium salt and the di- (L) -arginine salt as solids were subjected to stability testing at 25°C and 40°C.
  • the sample of sodium salt was 97.2%pure by HPLC initially, and after 6 weeks at 25°C, it was still 96.2%pure.
  • the same material held at 40°C was 94.8%pure after 3 weeks, and 93.6%pure after 6 weeks.
  • RRT relative retention times
  • the HPLC traces for the samples from these stability studies after 6 weeks at 25°C and 40°C respectively are shown in Figures 10 and 11.
  • the lower trace in each Figure is a sample used to measure the limit of quantitation (LOQ) ; the next trace above that represents the sample of Compound X used for salt formation; the next trace above that one is for the arginine salt after 6 weeks; and the next (top) trace is for the sodium salt after 6 weeks.
  • LOQ limit of quantitation
  • Compound X was also found to degrade photochemically; thus Compound X should be stored in dark or opaque containers for best shelf life.
  • Compound X is packaged in a container that substantially reduces exposure to light, preferably in an atmosphere at a relative humidity of 25-50%humidity and more preferably at a relative humidity of 30-40%or 30-45%.
  • Bacterial isolates were cultivated from -70°C frozen stocks by two consecutive overnight passages at 35°C in ambient air on 5%blood agar (Remel, Lenexa, Kans. ) .
  • Quality control and P. aeruginosa ATCC 27853 is from the American Type Culture Collection (ATCC; Rockville, Md. ) and PAO1 was received from Dr. K. Poole.
  • Strain NB27273 (BW25113 pspB: : Km r ) was obtained from the Keio transposon insertion collection.
  • the strain has the pspB gene replaced by a kanamycin resistance marker (BW25113 pspB: : Km r ) .
  • This strain was cured of the transposon in pspB via FLP recombinase using published methodology.
  • the resulting strain, BW25113 pspB was used as a host for multicopy vectors expressing key ⁇ -lactamases.
  • Multicopy plasmids directing constitutive expression of ⁇ -lactamases were established as follows: Synthetic, codon optimized genes encoding E.
  • coli KPC2 and SHV12-lactamases were made by DNA2.0 (Palo Alto, CA) .
  • Each of the synthetic fragments were designed to contain NotI and NcoI restriction sites at their termini, allowing ligation into a NotI/NcoI digested pET28a (+) derivative for protein expression.
  • the inserts in these vectors served as template DNA for PCR amplification of the gene encoding KPC2 and SHV12, using primer pairs E225 (tcgcCTCGAGgcgactgcgctgacgaatttgg) (SEQ ID NO: 1) and E202 (aatcGAATTCttactgaccattaacgcccaagc) (SEQ ID NO: 2) and E227 (tcgcCTCGAGgcgagcccgcaaccgctgga) (SEQ ID NO: 3) and E204 (aatcGAATTCttaacgctgccagtgctcaatc) (SEQ ID NO: 4) , respectively.
  • the codon optimized nucleotide sequences and relevant primer recognition information is shown below:
  • Plasmid pAH63-pstS (BlaP) is a derivative of plasmid pAH63 (J Bacteriol: 183 (21) : 6384–6393) made by cloning the TEM-1 (bla) promoter and signal peptide encoding region from plasmid pBAD (J Bacteriol. 1995 Jul. 177 (14) : 4121-30) into plasmid pAH63.
  • This fragment was PCR amplified from pBAD using primer pair E192 (ttcaCTGCAGtgaacgttgcgaagcaacggC) (SEQ ID NO: 13) and E194 (TCGAggatcctcgagagcaaaaacaggaaggcaaaatgccg) (SEQ ID NO: 14) , digested with PstI and BamHI and inserted into similarly digested plasmid pAH63. Therefore, expression of ⁇ -lactamases from pAH63-pstS (BlaP) based constructs is constitutive and the signal sequence is provided to direct these proteins to the periplasm.
  • Plasmid pAH63 based vectors are used for insertion into the genome in single copy, however, to provide higher expression levels to allow more sensitive detection of the susceptibility of compounds to the ⁇ -lactamases, the expression inserts contained in these vectors were moved to the replicative multicopy vector pBAD-Kan (J Bacteriol. 1995 Jul. 177 (14) : 4121-30) .
  • the pBAD18-kan vector also contains the TEM promoter region and signal sequence, (but lacks any intact ⁇ -lactamase genes) and was transformed into BW25113 pspB using standard protocols to generate the control strain NB27273-CDY0026. Expression of the ⁇ -lactamases was confirmed by verifying decreased susceptibility to example test antibiotics that are known substrates of KPC2 or SHV12.
  • MICs Minimal Inhibitory Concentrations were determined by the broth microdilution method in accordance with Clinical and Laboratories Institute (CLSI) guidelines. In brief, fresh overnight bacterial cultures were suspended in sterile saline, and adjusted to a 0.5 McFarland turbidity standard. Bacterial suspensions were then diluted in cation adjusted Mueller-Hinton Broth (MHB II; BBL) to yield a final inoculum of approximately 5x10 5 colony-forming units (CFU) /mL. A master plate of antibiotics was prepared at a concentration equivalent to hundred-fold the highest desired final concentration in 100%dimethyl sulfoxide (DMSO) .
  • DMSO dimethyl sulfoxide
  • the master antibiotic plate was then diluted by serial twofold dilution with a multichannel pipette.
  • the resulting dilution series of compounds were diluted 1: 10 with sterile water leading to a 10%DMSO final concentration.
  • a volume of 10 ⁇ L of the drug dilution series was transferred to 96-well assay plates.
  • Assay plates were inoculated with 90 ⁇ L of bacterial suspensions and incubated at 35-37°C for 20 hrs.
  • the assay plates were read using a microtiter plate reader (Molecular Devices) at 600nm as well as by visual observation with a reading mirror. The lowest concentration of the compound that prevented visible growth was recorded as the MIC. Performance of the assay was monitored by testing aztreonam against laboratory quality control strains in accordance with guidelines of the CLSI.
  • Table A Minimum Inhibitory Concentrations (MIC) against isogenic strains of E. coli, carrying various resistance determinants.
  • Compound X was tested on E. coli strain 25922 and an E. coli containing KPC-2 (Strain 2 above, which is a known carbapenemase from Klebsiella pneumoniae) , and exhibited these Inhibitory Concentrations (MIC) , in mg/mL.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Providing new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl) -2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl) amino)ethylidene)amino)oxy)-cyclopropanecarboxylic acid (referred to herein as compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.

Description

SALTS AND SOLID FORMS OF A MONOBACTAM ANTIBIOTIC FIELD OF THE INVENTION
The present invention relates to salts and crystal forms of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid that are suitable for commercial scale production, as well as pharmaceutical compositions containing these materials, methods of preparing them, and their use in therapy.
BACKGROUND
Over the past several decades, the frequency of antimicrobial resistance and its association with serious infectious diseases have increased at alarming rates. The increasing prevalence of resistance among nosocomial pathogens is particularly disconcerting. Of the over 2 million nosocomial (hospital-acquired) infections occurring each year in the United States, 50 to 60％are caused by antimicrobial-resistant strains of bacteria. The high rate of resistance to commonly used antibacterial agents increases the morbidity, mortality, and costs associated with nosocomial infections. In the United States, nosocomial infections are thought to contribute to or cause more than 77,000 deaths per year and cost approximately $5 to $10 billion annually.
Important causes of Gram-negative resistance include extended-spectrum β-lactamases (ESBLs) , serine carbapenemases (KPCs) and metallo-β-lactamases (for example NDM-1) in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis, high-level third-generation cephalosporin (AmpC) β-lactamase resistance among Enterobacter species and Citrobacter freundii, and multidrug-resistance genes observed in Pseudomonas, Acinetobacter, and Stenotrophomonas. The problem of antibacterial resistance is compounded by the existence of bacterial strains resistant to multiple antibacterials. For example, Klebsiella pneumonia harboring NDM-1 metallo-β-lactamase carries frequently additional serine-β-lactamases on the same plasmid that carries the NDM-1.
Thus there is a need for new antibacterials, particularly antibacterial compounds that are effective against existing drug-resistant microbes, or are less susceptible to development of new bacterial resistance. The current invention provides solid forms of such compounds that are especially well suited for commercial-scale production due to their handling properties under convenient operating conditions for manufacture.
Unpublished patent application number PCT/US2015/022011 describes certain monobactam antibiotics. One compound in that application that shows strong activity against Gram-negative bacteria, including strains that show resistance to other monobactams, is 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid, which is referred to herein as Compound X:
Figure PCTCN2016099482-appb-000001
For manufacturing pharmaceutical compounds and their formulations, it is important that the active compound be in a form that can be conveniently handled and processed in order to obtain a commercially viable, reliable, and reproducible manufacturing process. Compound X and many of its salts are solid at room temperature, and can be produced in various solid forms, depending on the conditions used to produce, purify or crystallize the material. The existence of multiple solid forms, often referred to as polymorphs, is well known for solid pharmaceutical compounds, and the chemical and physical stability as well as handling properties of such compounds often depend on which solid form is used. Accordingly, the selection of a particular solid form of the active drug substance (e.g., a salt form, hydrated or solvated form, or polymorphic form) is often very important in the design of a reliable and reproducible production process, and in storage, handling and distribution of a safe and effective form of the drug substance.
It is generally found that there are advantages in manufacturing a particular solid-state form of a pharmaceutical ingredient, and these are described in "Handbook  of Pharmaceutical Salts； Properties, Selection and Use" , P. Heinrich Stahl, Camille G. Wermuth (Eds. ) (Verlag Helvetica Chimica Acta, Zurich) . Methods of manufacturing solid-state forms are also described in "Practical Process Research and Development" , Neal G. Anderson (Academic Press, San Diego) and "Polymorphism: In the Pharmaceutical Industry" , Rolf Hilfiker (Ed) (Wiley VCH) .
The present inventors have discovered certain salts and polymorph forms of Compound X that are particularly suitable for use in the manufacture, storage or administration of Compound X as described herein.
It is important for a drug product to be stable enough to avoid significant degradation when it is shipped and stored under commercially practical conditions. The inventors have discovered that Compound X in solution is preferably used and stored at a pH between 4 and 6, preferably between 4.0 and 5.5, for maximum stability in the presence of moisture. Optimal solution stability is achieved at a pH of about 4.0 to 5.5 Accordingly, the invention provides pharmaceutical compositions comprising Compound X at a pH between 4 and 6, preferably between 4.0 and 5.5, and more preferably at a pH of about 5±0.5 or at pH of 5±0.2. Suitable compositions comprise Compound X in an aqueous solution, such as a dextrose or saline solution, which may be isotonic, and may contain other substances such as stabilizers, antioxidants, buffers or pH modifiers, nutrients, and the like. In some of these embodiments, the desired pH is achieved by combining Compound X and a pH modifier suitable to achieve the desired pH in an aqueous solution. Suitable pH modifiers include but are not limited to sodium hydroxide, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium hydroxide, amines such as TRIS (tris (hydroxymethyl) aminomethane) , and amino acids such as arginine, lysine, histidine, and the like. Known monobactams, including aztreonam, have been formulated with arginine.
Suitable pH can be achieved by adding a pH modifier to an aqueous solution of Compound X, or by adding Compound X to an aqueous solution containing the pH modifier. Appropriate quantities of the pH modifier and Compound X can be readily determined by the skilled person. Suitable pH modifiers include sodium hydroxide and arginine. Thus a solution or suspension of Compound X can be treated with sodium hydroxide, or with arginine, to produce a solution comprising a sodium salt or an arginine salt of the Compound. Moreover, this solution can be lyophilized to remove the water and any co-solvents present, leaving a lyophilized solid that comprises  Compound X along with the pH modifier, or a salt formed by Compound X and the pH modifier, e.g., the sodium salt or arginine salt of Compound X.
Furthermore, in accordance with the present invention, there are provided a number of solid forms of Compound X that provide handling properties suitable for manufacture on industrial scale, along with methods of producing these polymorphs.
The following enumerated embodiments of the invention are representative:
1. An arginine salt of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid. In some embodiments, the salt is an (L) -arginine salt.
2. A sodium salt of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid.
3. A hydrated solid form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid.
4. The hydrated solid form according to embodiment 3, which consists mainly of a trihydrate of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid.
5. A method to prepare the hydrated solid form according to embodiment 4, which comprises contacting 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid with an atmosphere having relative humidity between 25％and 50％at a temperature between 20℃ and 30℃.
6. A pharmaceutical composition comprising a compound according to any one of embodiments 1-4 and at least one pharmaceutically acceptable carrier or excipient.
7. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 1) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 6.6. 13/4, and 18.8. In some embodiments, Form 1 has additional XRPD peaks as described below.
8. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 2) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 7.5, 19.3, and 20.0. In some embodiments, Form 2 has additional XRPD peaks as described below.
9. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 3) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 7.3, 18.9, and 21.2. In some embodiments, Form 3 has additional XRPD peaks as described below.
10. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 4) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 7.0, 8.6, 19.3 and 20.9. In some embodiments, Form 4 has additional XRPD peaks as described below.
11. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy)  cyclopropanecarboxylic acid (Form 5) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 7.3, 9.3, and 27.8. In some embodiments, Form 5 has additional XRPD peaks as described below.
12. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 6) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 8.1, 9.2, and 12.8； and optionally by additional peaks at 21.2 and 24.7. In some embodiments, Form 6 has additional XRPD peaks as described below.
13. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 7) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 6.7, 7.3 and 20.3. In some embodiments, Form 7 has additional XRPD peaks as described below.
14. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 8) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 6.2, 21.8 and 25.9. In some embodiments, Form 8 has additional XRPD peaks as described below.
15. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 9) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 6.3, 12.6, and 22.3； and optionally by one or more additional peaks selected from 22.1, 23.1, 27.0 and 27.5. In some embodiments, Form 9 has additional XRPD peaks as described below.
16. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 10) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 6.6, 11.0, and 16.5； and optionally by one or more additional peaks selected from 22.2 and 23.4. In some embodiments, Form 10 has additional XRPD peaks as described below.
17. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 11) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 7.4, 9.7, and 29.3； and optionally by one or more additional peaks selected from peaks at 17.0, 19.5, 22.2, 26.3 and 28.1. In some embodiments, Form 11 has additional XRPD peaks as described below.
18. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 12) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 19.0, 20.4, and 24.0； and optionally by one or more additional peaks selected from peaks at 7.3, 24.7, and 27.2. In some embodiments, Form 12 has additional XRPD peaks as described below.
19. A pharmaceutical composition comprising 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid and arginine.
20. The pharmaceutical composition of claim 19, which further comprises a pharmaceutically acceptable carrier.
21. The pharmaceutical composition of claim 20, wherein the carrier is aqueous.
22. The pharmaceutical composition of claim 21, which is at a pH of about 5.0.
23. The pharmaceutical composition of claim 21 or 22, which further comprises at least one excipient selected from sucrose, fructose, trehalose, mannitol, and lactose.
24. A compound according to any one of claims 1-4, or a crystalline form thereof according to any one of claims 7 to 18, for use in therapy.
25. The compound of claim 24, wherein the therapy is the treatment of a Gram-negative bacterial infection.
26. The compound according to claim 24, wherein the bacterium causing the Gram-negative bacterial infection is selected from Citrobacter, Enterobacter, Eschirichia, Haemophilus, Klebsiella, Morganella, Moraxella, Pseudomonas, Proteus, Salmonella, Serratia, Shigella, and Neisseria bacteria.
27. Use of a compound according to any one of claims 1 to 4, or a crystalline form thereof according to any one of claims 7 to 18, in the manufacture of a medicament for the treatment of a Gram-negative bacterial infection.
28. Use, according to claim 27, wherein the bacterium causing the Gram-negative bacterial infection is a species selected from Citrobacter, Enterobacter, Eschirichia, Haemophilus, Klebsiella, Morganella, Moraxella, Pseudomonas, Proteus, Salmonella, Serratia, Shigella, and Neisseria bacteria.
29. A method of treatment for a Gram-negative infection, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 4, or a crystalline form according to any one of claims 7 to 18, or a pharmaceutical composition according to any one of claims 19-23.
30. The method of claim 29, wherein the bacterium causing the Gram-negative bacterial infection is a species selected from Citrobacter, Enterobacter,  Eschirichia, Haemophilus, Klebsiella, Morganella, Moraxella, Pseudomonas, Proteus, Salmonella, Serratia, Shigella, or Neisseria bacteria.
Thus, in one aspect, the invention provides a crystalline form of Compound X (Form 1) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 6.6, 13.4, and 18.8. In one embodiment, Form 1 exhibits at least the following characteristic X-ray powder diffraction peaks: 6.6, 13.4, 16.6, 17.9, 18.8, 20.3, 25.1, and 28.9. In another embodiment, Form 1 exhibits at least the characteristic X-ray powder diffraction peaks shown in List 1, or any subset of at least five peaks selected from List 1. In yet another embodiment, Form 1 exhibits an X-ray powder diffraction pattern substantially the same as that shown in Figure 1.
In another aspect, the invention provides a crystalline form of Compound X (Form 2) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 7.5, 19.3 and 20.0. In one embodiment, Form 2 exhibits at least the following characteristic X-ray powder diffraction peaks: 6.7, 7.5, 13.3, 13.7, 15.3, 17.9, 18.7, 19.3 and 20.0. In another embodiment, Form 2 exhibits at least the characteristic X-ray powder diffraction peaks shown in List 2, or any subset of at least five peaks selected from List 2. In yet another embodiment, Form 2 exhibits an X-ray powder diffraction pattern substantially the same as that shown in Figure 2.
In another aspect, the invention provides a crystalline form of Compound X (Form 3) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 7.3, 18.9, and 21.2； and optionally further including a peak at 8.3. In one embodiment, Form 3 exhibits at least the following characteristic X-ray powder diffraction peaks: 7.3, 13.9, 16.7, 18.9, 20.3, 21.2, and 24.6. In another embodiment, Form 3 exhibits at least the characteristic X-ray powder diffraction peaks shown in List 3, or any subset of at least five peaks selected from List 3. In yet another embodiment, Form C exhibits an X-ray powder diffraction pattern substantially the same as that shown in Figure 4.
In another aspect, the invention provides a crystalline form of Compound X (Form 4) which exhibits at least the following characteristic X-ray powder diffraction peaks  (expressed in degrees 2θ) : 7.0, 8.6, 19.3 and 20.9. In one embodiment, Form 4 exhibits at least the following characteristic X-ray powder diffraction peaks: 7.0, 8.6, 15.2, 17.0, 18.0, 19.3, 20.9, 24.5, and 26.9. In another embodiment, Form 4 exhibits at least the characteristic X-ray powder diffraction peaks shown in List 4, or any subset of at least five peaks selected from List 4. In yet another embodiment, Form 4 exhibits an X-ray powder diffraction pattern substantially the same as that shown in Figure 5.
In another aspect, the invention provides a crystalline form of Compound X (Form 5) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 7.3, 9.3, and 27.8； and optionally further including a peak at 19.9. In one embodiment, Form 5 exhibits at least the following characteristic X-ray powder diffraction peaks: 7.3, 9.3, 16.3, 18.6, 19.2, 19.9, 21.7, 24.1, 24.9, 27.3, 27.8 and 29.8. In another embodiment, Form 5 exhibits at least the characteristic X-ray powder diffraction peaks shown in List 5, or any subset of at least five peaks selected from List 5. In yet another embodiment, Form 5 exhibits an X-ray powder diffraction pattern substantially the same as that shown in Figure 6.
In another aspect, the invention provides a crystalline form of Compound X (Form 6) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 8.1, 9.2, 12.8, 21.2, and 24.7. In one embodiment, Form 6 exhibits at least the following characteristic X-ray powder diffraction peaks: 8.1, 9.2, 12.8, 13.9, 14.4, 16.7, 20.1, 21.2, 24.7, and 26.6. In another embodiment, Form 6 exhibits at least the characteristic X-ray powder diffraction peaks shown in List 6, or any subset of at least five peaks selected from List 6. In yet another embodiment, Form 6 exhibits an X-ray powder diffraction pattern substantially the same as that shown in Figure 7.
In another aspect, the invention provides a crystalline form of Compound X (Form 7) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 6.7, 7.3 and 20.3. In one embodiment, Form 7 exhibits at least the following characteristic X-ray powder diffraction peaks: 6.7, 7.3, 17.6, 18.0, 20.3, and 24.9. In another embodiment, Form 7 exhibits at least the characteristic X-ray powder diffraction peaks shown in List 7, or any subset of at least five peaks selected  from List 7. In yet another embodiment, Form 7 exhibits an X-ray powder diffraction pattern substantially the same as that shown in Figure 8.
In another aspect, the invention provides a crystalline form of Compound X (Form 8) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 6.2, 21.8, and 25.9. In one embodiment, Form 8 exhibits at least the following characteristic X-ray powder diffraction peaks: 6.2, 17.8, 20.7, 21.8, and 25.9. In another embodiment, Form 8 exhibits at least the characteristic X-ray powder diffraction peaks shown in List 8, or any subset of at least five peaks selected from List 8. In yet another embodiment, Form 8 exhibits an X-ray powder diffraction pattern substantially the same as that shown in Figure 9.
In one aspect of the invention, the polymorphs of the invention have crystalline properties and are preferably at least 50％crystalline, more preferably at least 60％crystalline, still more preferably at least 70％crystalline and most preferably at least 80％crystalline. Crystallinity can be estimated by conventional X-ray diffractometry techniques or by infra-red spectroscopic techniques.
In some embodiments, the solid form of Compound X comprises one or more of the Forms described herein. A solid form of Compound X can include two or more of these Forms, i.e., it can be a mixture of two or more Forms. In some embodiments, a sample of the solid form mainly consists of a single Form selected from Forms 1-8, meaning that 50％or more of the material is of one solid Form. Relative amounts of various Forms in a mixture can be determined from XRPD data. As described herein, some of the Forms can evolve or interconvert under suitable conditions, such as  Forms  4 and 5, which can occur as a mixture, and can interconvert depending on the relative humidity and temperature at which the material is maintained.
In one aspect of the invention, the polymorphs of the invention are from 50％, 60％, 70％, 80％or 90％to 95％, 96％, 97％, 98％, 99％or 100％crystalline.
In the present specification, X-ray powder diffraction peaks (expressed in degrees 2θ) are measured using copper X-rays with a wavelength of
Figure PCTCN2016099482-appb-000002
 (alpha1) and
Figure PCTCN2016099482-appb-000003
Figure PCTCN2016099482-appb-000004
 (alpha2) . Peak locations are reported in degrees 2θ and are understood to be subject  to small numerical variations and it should thus be understood that the angles are subject to variation of ±0.2°.
The crystalline forms of the present invention can exist in either unsolvated or solvated forms. The term 'solvate' is used herein to describe a molecular complex comprising the compound of the invention and an amount of one or more pharmaceutically acceptable solvents. Examples of pharmaceutically acceptable solvents include ethanol and water. The term 'hydrate'is employed when the solvent is water. Several polymorphs of Compound X as described herein are hydrates.
In one aspect, the invention provides a salt or crystalline form defined herein for use in therapy. In another aspect, the invention provides a method of treatment by therapy, comprising administering to a subject in need thereof a pharmaceutically acceptable amount of a salt or crystalline form according to the invention.
In one aspect, the invention provides the use of a salt or crystalline form defined herein in the manufacture of a medicament for use in therapy.
In one embodiment, the therapy is the treatment of an infection caused by a Gram-negative bacterium.
The invention also provides processes for the preparation of the crystalline forms described herein. Thus, in one aspect, the invention provides a process for the preparation of any of  Forms  1, 2, 3, 4, 5, 6, 7, and 8 as described herein comprising the crystallisation of the desired Form from a solution of Compound X, using solvent systems and conditions described in the Examples provided herein.
In the context of the present invention, references herein to "treatment" include references to curative, palliative and prophylactic treatment, unless there are specific indications to the contrary. The terms "therapy, "therapeutic" and "therapeutically" should be construed in the same way.
Compound X is typically administered by injection or infusion, and may be prepared for administration by dissolving Compound X in a suitable amount of water or of an aqueous solution such as dextrose or saline, e.g., isotonic dextrose or saline.
Optionally, the formulated composition may also include a pH modifier such as sodium hydroxide, sodium bicarbonate, sodium carbonate, potassium hydroxide, potassium carbonate, calcium hydroxide, magnesium hydroxide, meglumine, TRIS, or an amino acid (e.g., lysine, histidine, or arginine) in quantity sufficient to provide a desired pH, such as a pH between 4 and 6. While the amino acids used in the examples were (L) -amino acids, a (D) -amino acid or racemic mixture could be used instead.
Pharmaceutical compositions comprising Compound X in solution are typically adjusted to a pH between 4.5 and 5.5, often or at a pH of about 5, such as between pH 4.8 and 5.2.
In some embodiments, Compound X is formulated with a pH modifier in aqueous solution, and is then lyophilized to a solid form for storage and distribution. For administration, one can reconstitute the lyophilized drug product by adding an aqueous carrier, typically a sterile aqueous carrier such as water or an isotonic dextrose or saline solution, or other IV solution such as Ringer’s, Lactated Ringer’s, or Hartmann’s solution. Accordingly, the invention also provides a lyophilizate (asolid prepared by lyophilization) comprising Compound X and a pH modifier such as those mentioned above, e.g. (L) -arginine, (L) -lysine, meglumine, TRIS, of sodium hydroxide. Optionally, other excipients such as sucrose may be included. In one embodiment, a solution of Compound X and arginine (two equivalents) is prepared, and the pH is adjusted to a pH between 4.8 and 5.2 using, for example, sodium hydroxide or hydrochloric acid as needed. The solution is then lyophilized to a white or slightly yellow solid, which is stable for storage and can readily be reconstituted with a suitable sterile aqueous solution for intravenous administration.
In another embodiment, a solution of Compound X, sucrose, and arginine (two equivalents) in water suitable for injection is prepared, and the pH is adjusted to a pH between 4.8 and 5.2 using, for example, sodium hydroxide or hydrochloric acid as needed. The solution is then lyophilized to a white or slightly yellow solid, which is stable for storage and can readily be reconstituted with a suitable sterile aqueous solution for intravenous administration.
The salts and crystalline forms of the present invention may be administered alone or in combination with one or more other drugs. Generally, they will be administered as a formulation in association with one or more pharmaceutically acceptable excipients. The term “excipient” is used herein to describe any ingredient  other than the compound (s) of the invention which may impart either a functional (i.e., drug release rate controlling) and/or a non-functional (i.e., processing aid or diluent) characteristic to the formulations. The choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form. Pharmaceutical compositions may also comprise a carrier, which is a substantially inert material, often a liquid, used to dilute the active ingredient (s) . Suitable carriers are known in the art, and include sterile water and sterile solutions of saline or dextrose, for example.
Pharmaceutical compositions suitable for the delivery of the solid forms of Compound X and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in REMINGTON’S PHARMACEUTICAL SCIENCES, 19th Edition (Mack Publishing Company, 1995) .
For administration to human patients, the total daily dose of the salt or crystalline form is typically in the range 1000 mg to 10,000 mg, or between 2000 mg and 8000 mg, or between 3000 mg and 8000 mg, or between 4000 mg and 6000 mg, depending on the condition of the subject and parameters such as the subject’s body weight, age, and gender. The total daily dose may be administered in a single dose, or it may be divided into two or more doses and may, at the physician's discretion, fall outside of the typical range given herein. Typically, the daily dosage would be delivered via intravenous injection or by infusion, and would be administered in one, two, three or four doses, that cumulatively provide the desired total daily dosage. Infusion may be rapid, or it may be performed over a period of between about 15 minutes and 4 hours, commonly over a period of 1-3 hours. A typical dosing schedule would provide three or four infusions daily, each lasting 0.25-2 hours or 0.25-3 hours, delivering 1 to 2 or 1 to 2.5 grams of Compound X per dose, and a typical total daily dose would be 3-8 grams. For example, a dosing schedule may deliver 2 grams of Compound X per infusion, with three one-hour infusions per day. Alternatively, a single infusion of 2-6 grams, or 3-5 grams over 1 or 1.5 or 2 or 2.5 or 3 hours may be used. The above dosages are based on an average human subject having a weight of about 60kg to 70kg, and may be scaled suitably for other subjects. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.
Brief Description of the Figures
The invention will now be illustrated by the following non-limiting examples. In the examples the following figures are presented:
Figure 1: X-ray powder diffraction pattern of Form 1.
Figure 2: X-ray powder diffraction pattern of Form 2.
Figure 3: X-ray powder diffraction pattern of Form 1 after stirring with acetone, overlaid by the XRPD for Form 1 for comparison.
Figure 4: X-ray powder diffraction pattern of Form 3.
Figure 5: X-ray powder diffraction pattern of Form 4.
Figure 6A: X-ray powder diffraction pattern of Form 5 overlaid on XPRD for Figure 4.
Figure 6B: X-ray powder diffraction pattern of Form 5 from larger scale preparation.
Figure 7: X-ray powder diffraction pattern of Form 6.
Figure 8: X-ray powder diffraction pattern of Form 7.
Figure 9: X-ray powder diffraction pattern of Form 8.
Figure 10: X-ray powder diffraction pattern of Form 9.
Figure 11: X-ray powder diffraction pattern of Form 10.
Figure 12: X-ray powder diffraction pattern of Form 11.
Figure 13: X-ray powder diffraction pattern of Form 12.
General Experimental Details
Each sample (few milligrams) is placed between three polymer foils (
Figure PCTCN2016099482-appb-000005
and /or polypropylene) . It is worth noting that
Figure PCTCN2016099482-appb-000006
exhibits a broad peak with a weak intensity around 2θ ＝ 5.5 °.
The sample is then placed in a PANALYTICAL X’PERT PRO MPD diffractometer configured in transmission mode, and analyzed using conditions indicated below.
The analyses are performed between 2 ° and 50 ° (unless stated otherwise) .
Figure PCTCN2016099482-appb-000007
Figure PCTCN2016099482-appb-000008
Measurement type: Repeated scan (3 /5 /20 times)
All starting materials, building blocks, reagents, acids, bases, dehydrating agents, solvents, and catalysts utilized to synthesis the compounds of the present invention are either commercially available or can be produced by organic synthesis methods known to one of ordinary skill in the art (Houben-Weyl 4th Ed. 1952, METHODS OF ORGANIC SYNTHESIS, Thieme, Volume 21) .
General Conditions
Mass spectra were acquired on LC-MS, SFC-MS, or GC-MS systems using electrospray, chemical and electron impact ionization methods from a range of instruments of the following configurations: Waters ACQUITY UPLC system and equipped with a ZQ 2000 or SQD MS system where (M+1) refers to the protonated molecular ion of the chemical species, (M+) refers to the unprotonated quaternary ammonium cation, (M+Na) refers to the sodium-incorporated ion and (M-1) refers to the deprotonated molecular ion of the chemical species.
NMR spectra were run on Bruker AVANCE 500MHz or Varian 400MHz NMR spectrometers using ICON-NMR, under TopSpin program control. Spectra were measured at 298K, unless indicated otherwise, and were referenced relative to the solvent resonance.
Instrumentation
MS Methods: Using Agilent 1100 HPLC systems with an Agilent 6110 Mass Spectrometer
Method 2m_acidic:
Figure PCTCN2016099482-appb-000009
Method 2m_acidic_polar:
Figure PCTCN2016099482-appb-000010
Figure PCTCN2016099482-appb-000011
Preparation of Compound X
Intermediate A: ( (2S, 3S) -3- ( ( (benzyloxy) carbonyl) amino) -1- (2, 4-dimethoxybenzyl) -4-oxoazetidin-2-yl) methyl methanesulfonate.
Figure PCTCN2016099482-appb-000012
To a solution of benzyl ( (2S, 3S) -1- (2, 4-dimethoxybenzyl) -2- (hydroxymethyl) -4-oxoazetidin-3-yl) carbamate (5.37 g, 13.41 mmol) and TEA (3.72 mL, 26.8 mmol) in DCM at 0 ℃ was added methanesulfonyl chloride (MsCl) (1.15 mL, 14.75 mmol) . After stirring at 0 ℃ for 1 h, it was diluted with water/DCM and the layers were separated. The aqueous layer was extracted with DCM (2x) and the combined organic layers were washed with brine, dried over Na2SO4 and concentrated in vacuo. The crude residue was taken up in toluene and concentrated (2x) , affording the title compound as an off white solid. It was used as such in subsequent reactions. LCMS: Rt ＝ 0.86 min, m/z ＝479.2 (M+1) Method 2m_acidic.
The starting material for this step can be made using the following approaches or some combination of steps based on these approaches. In a first approach, a protected chiral aldehyde is condensed with 2, 4-dimethoxybenzylamine to make a chiral imine.
Figure PCTCN2016099482-appb-000013
The chiral aldehyde is known, and can be made from citric acid:
Figure PCTCN2016099482-appb-000014
The chiral imine can be reacted with protected forms of glycine such as these:
Figure PCTCN2016099482-appb-000015
and
Figure PCTCN2016099482-appb-000016
The requisite mixed anhydride for the second option can be prepared from CBZ-protected glycine and isopropyl chloroformate in dichloromethane. (DMB refers to a 2, 4-dimethoxybenzyl group) . The dioxolane of this protected intermediate is then  hydrolyzed under mild acidic conditions and oxidized to an aldehyde, which can be easily reduced with, e.g. sodium borohydride, to provide the di-protected primary alcohol as shown.
Figure PCTCN2016099482-appb-000017
The primary alcohol of this intermediate can be converted into a leaving group, for example by treating with iodine and triphenylphosphine to produce a primary iodide, or by treating with a base and a sulfonyl chloride to produce e.g. a mesylate or tosylate. This activated intermediate reacts readily with hydroxyethylamine as shown in step 1 below.
Intermediate B: 3- ( ( (2R, 3S) -3-amino-4-oxoazetidin-2-yl) methyl) oxazolidin-2-one.
Figure PCTCN2016099482-appb-000018
Step 1: Benzyl ( (2R, 3S) -1- (2, 4-dimethoxybenzyl) -2- ( ( (2-hydroxyethyl) amino) methyl) -4-oxoazetidin-3-yl) carbamate. To a solution of ( (2S, 3S) -3- ( ( (benzyloxy) carbonyl) amino) -1- (2, 4-dimethoxybenzyl) -4-oxoazetidin-2-yl) methyl methanesulfonate (6.43g, 13.4 mmol) in Acetonitrile (44.8 ml) was added ethanolamine (8.13 ml, 134 mmol) followed by DIEA (7.0 ml, 40 mmol) . The solution was heated to 80℃ for 20 h, whereupon it was cooled to rt, diluted with EtOAc, washed  with water, dried over Na2SO4 and concentrated in vacuo, to afford the title compound (4.47 g, 75％) as a white solid. LCMS: Rt ＝ 0.60 min, m/z ＝ 444.2 (M+1) .
Step 2: Benzyl ( (3S, 4R) -1- (2, 4-dimethoxybenzyl) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) azetidin-3-yl) carbamate. To a solution of benzyl ( (2R, 3S) -1- (2, 4-dimethoxybenzyl) -2- ( ( (2-hydroxyethyl) amino) methyl) -4-oxoazetidin-3-yl) carbamate (4.47g, 10.08 mmol) in chloroform (50 ml) was added carbonyldiimidazole (CDI) (4.90 g, 30.2 mmol) . After stirring at rt for 30 min, the reaction mixture was concentrated in vacuo. The crude residue was purified via silica gel chromatography (MeOH-DCM, 0-5％) , affording the title compound (3.84 g, 81％) as a white foam. LCMS: Rt ＝ 0.76 min, m/z ＝ 470.1 (M+1) .
Step 3: Benzyl ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) azetidin-3-yl) carbamate. Prepared analogously to a preparation in Mastalerz et al. J. Med. Chem. 1988, 31, 1190, using benzyl ( (3S, 4R) -1- (2, 4-dimethoxybenzyl) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) azetidin-3-yl) carbamate (3.84 g, 8.18 mmol) , K2S2O8 (3.10 g, 11.5 mmol) and K2HPO4 (1.852 g, 10.6 mmol) in ACN: water (2: 1, 136 mL) and heating for 40 min at 90 ℃. More K2S2O8 (663 g, 2.45 mmol) and K2HPO4 (370 mg, 2.13 mmol) were added and the mixture was heated for another 3 h. More K2S2O8 (332 mg, 1.23 mmol) and K2HPO4 (185 mg, 1.06 mmol) were added, and it was heated for an additional 2 h, whereupon it was concentrated in vacuo, removing most of the ACN. The mixture was diluted with brine/EtOAc and the layers were separated. The aqueous layer was extracted with EtOAc (3x) and the combined organic layers were dried over Na2SO4. The crude residue was purified via silica gel chromatography (EtOAc-Heptane, 0-100％then MeOH-DCM, 10％) to afford the title compound (1.61 g, 62％) as a beige foam. LCMS: Rt ＝ 0.51 min, m/z ＝ 320.0 (M+1) Method 2m_acidic.
Step 4: 3- ( ( (2R, 3S) -3-amino-4-oxoazetidin-2-yl) methyl) oxazolidin-2-one. Prepared according to
Figure PCTCN2016099482-appb-000019
et al. Bioorg. Med. Chem. Lett. 2012, 22, 5293, using benzyl ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) azetidin-3-yl) carbamate (96 mg, 0.30 mmol) and Pd/C 10％Degussa type 101 (10％, 64 mg) and hydrogen in EtOH: MeOH (4: 1, 1.5 mL) for 1 h. The crude residue was used as such in the following step. LCMS: Rt ＝ 0.11 min, m/z ＝ 186.0 (M+1) Method 2m_acidic.
Compound X: 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid.
Step 1: Benzhydryl 1- ( ( (Z) - (1- (2- ( (tert-butoxycarbonyl) amino) thiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) azetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylate. To a solution of (Z) -2- ( (1- ( (benzhydryloxy) carbonyl) cyclopropoxy) imino) -2- (2- ( (tert-butoxycarbonyl) amino) thiazol-4-yl) acetic acid (854 mg, 1.59 mmol) prepared according to published patent application US2011/0190254, Intermediate B (324 mg, 1.75 mmol) and HATU (785 mg, 2.07 mmol) in DMF (7.9 mL) , DIPEA was added (832 μL, 4.77 mmol) . After 1 h of stirring, it was poured into water and extracted with EtOAc. Brine was added to the aqueous layer, and it was further extracted with ethyl acetate (EtOAc) (3x) . The combined organic layers were dried over Na2SO4 and concentrated in vacuo. The crude residue was purified via silica gel chromatography (0-10％MeOH-DCM) to afford the title compound (1.09 g, 97％) as a beige foam. LCMS: Rt ＝ 0.97 min, m/z ＝705.3 (M+1) Method 2m_acidic.
Instead of HATU, a variety of other coupling reagents can be used, such as any of the typical carbodiimides, or CDMT (2-chloro-4, 6-dimethoxy-1, 3, 5-triazine) and N-methylmorpholine to form the amide bond generated in Step 1.
Step 2: (3S, 4R) -3- ( (Z) -2- ( (1- ( (benzhydryloxy) carbonyl) cyclopropoxy) imino) -2- (2- ( (tert-butoxycarbonyl) amino) thiazol-4-yl) acetamido) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) azetidine-1-sulfonic acid. Benzhydryl 1- ( ( (Z) - (1- (2- ( (tert-butoxycarbonyl) amino) thiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) azetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylate (1.00 g, 1.42 mmol) in DMF (7.0 mL) at 0 ℃ was treated with SO3·DMF (448 mg, 2.84 mmol) . After 2 h of stirring at rt, the solution was poured into ice-cold brine and extracted with EtOAc (3x) . The combined organic layers were dried over Na2SO4 and concentrated in vacuo, affording the title compound (assumed quantitative) as a white solid. LCMS: Rt ＝0.90 min, m/z ＝ 785.2 (M+1) Method 2m_acidic.
Step 3: 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid.
Figure PCTCN2016099482-appb-000020
To a solution of (3S, 4R) -3- ( (Z) -2- ( (1- ( (benzhydryloxy) carbonyl) cyclopropoxy) imino) -2- (2- ( (tert-butoxycarbonyl) amino) thiazol-4-yl) acetamido) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) azetidine-1-sulfonic acid (1.10 g, 1.40 mmol) in DCM (1.5 mL) at 0℃, TFA (5.39 mL, 70.0 mmol) was added, and after 10 minutes, the ice bath was removed. Additional TFA (3.24 mL, 42.0 mmol) was added after 1 hr at rt and the solution was diluted with DCM and concentrated in vacuo after an additional 30 min. Optionally, anisole may be added to the TFA reaction to help reduce by-product formation, which may increase the yield of desired product in this step. The crude residue was purified by reverse phase prep HPLC (XSelect CSH, 30 x 100 mm, 5 μm, C18 column； ACN-water with 0.1％formic acid modifier, 60 mL/min) , affording the title compound (178 mg, 23％) as a white powder. LCMS: Rt ＝ 0.30 min, m/z ＝ 518.9 (M+1) Method 2m_acidic； 1H NMR (400 MHz, DMSO-d6) δ 9.27 (d, J ＝ 9.0 Hz, 1H) 6.92 (s, 1H) 5.23 (dd, J ＝ 9.1, 5.7 Hz, 1H) 4.12-4.23 (m, 3H) 3.72-3.62 (m, 2H assumed； obscured by water) 3.61-3.52 (m, 1H assumed； obscured by water) 3.26 (dd, J ＝ 14.5, 5.9 Hz, 1H) 1.36 (s, 4H) . 1H NMR (400 MHz, D2O) δ 7.23 (s, 1H) , 5.48 (d, J ＝ 5.8 Hz, 1H) , 4.71-4.65 (m, 1H) , 4.44 (t, J ＝ 8.2 Hz, 2H) , 3.89-3.73 (m, 3H) , 3.54 (dd, J ＝ 14.9, 4.9 Hz, 1H) , 1.65-1.56 (m, 2H) , 1.56-1.46 (m, 2H) . The product of this process is amorphous. Compound X can be crystallized from acetone, ethanol, citrate buffer at pH 3 (50 mM) , or acetate buffer at pH 4.5 (50 mM) , in addition to solvents discussed below.
Instrumentation
DSC: Pyris Diamond DSC, Nitrogen gas (20 mL/min)
TGA: Pyris 1 TGA, Nitrogen gas (20 mL/min) , scanning at 10℃/min
XRPD: X’Pert Pro MPD Panalytical, Cu anode, 40kV at 40 mA current
Tube anode: (Cu)
Generator tension: 40 kV
Tube current: 40 mA
Start angle [2 θ] : 3
End angle [2 θ] : 40
Scan time 2 minutes
Form 1 and Form 2
Compound X was prepared as described above and crystallized from solvent to provide materials having the X-ray powder diffraction pattern (XRPD) in Figure 1 or Figure 2. These represent two separate batches of crystalline material, and are referred to herein as Form 1 and Form 2. Forms 1 and 2 have some similar XRPD peaks, and the XRPD for Form 2 shows broadened lines, so the product identified as Form 2 may contain some Form 1 material, or both samples may be mixtures of crystal forms. These two Forms were substantially anhydrous, containing less than about 1％water by weight according to Karl Fischer analysis.
Compound X of Form 1 (1.2 g) was suspended in 12 mL acetone and stirred for 3 days at 20℃. The sample does not appear to evolve: while some line broadening occurred, the XRPD of the product (Figure 3) still appears generally consistent with Form 1.
The sample giving the XRPD in Figure 1 exhibited a strong exotherm during DSC at about 205℃, and gradual loss of mass via TGA amounting to about 2％loss by 180℃.
The sample that produced the XRPD in Figure 2 (Form 2) exhibited a strong exotherm during DSC at about 203℃, and slightly greater loss of mass (3.7％) by 160℃compared to Form 1.
List 1: XRPD peak listing for Form 1 (2Theta: most intense peaks are underlined)
Figure PCTCN2016099482-appb-000021
Figure PCTCN2016099482-appb-000022
Form 1 can also be characterized by a subset of these peaks, for example the peaks at 6.6, 13.4 and 18.8.
List 2: XRPD peak listing for Form 2 (2Theta: most intense peaks are underlined)
Figure PCTCN2016099482-appb-000023
Form 2 can also be characterized by a subset of these peaks, for example the peaks at 7.5, 19.3 and 20.0.
Form 3
Compound X of Form 1 was suspended in methanol and within a few minutes it evolved into a sticky solid product. The product exhibited the XRPD pattern shown in Figure 4, and is referred to herein as Form 3. Note that a different form (Form 8) was obtained after longer stirring in methanol on a larger scale, as described below； thus  Form 3 may be a transient form or a mixture formed as Form 1 evolves under these conditions.
List 3: XRPD peak listing for Form 3 (2Theta: most intense peaks are underlined)
Figure PCTCN2016099482-appb-000024
Form 3 can also be characterized by a subset of these peaks, for example the peaks at 7.3, 18.9 and 21.2.
Form 4
Compound X of Form 1 (1.2 g) was suspended in water (12 mL) and stirred at 20℃ for 3 days. The product exhibited the XRPD pattern shown in Figure 5, and is referred to herein as Form 4. The XRPD is from a sample dried with filter paper. The TGA analysis for Form 4 shows gradual loss of weight beginning about 40℃ and becoming rapid around 100℃, to a plateau at about 60％of original weight at 120-170℃. Above that temperature, a gradual loss of weight is seen. The early loss of mass is consistent with loss of water from Form 4, and with the DSC, which shows a strong endotherm in the same temperature range and a plateau at about 110-180℃. Similarly, the dynamic vapor sorption (DVS) analysis for Form 4 shows a rapid loss of  about 20％of sample mass as relative humidity dropped to around 50％, after which cycling to lower then higher then lower and then higher relative humidity produced corresponding decrease, increase, decrease and increase of sample mass with a minimum mass about 65％of original, and maximum at about 80％of original mass. Form 4 is thus a hydrated form, and evolves depending on RH. The degree of hydration of the sample varies with relative humidity from an anhydrous form at very low humidity, to a trihydrate at RH about 20-50％, to a hexahydrate at RH above 60％. A sample of Form 4 dried at 0％relative humidity (RH) produces an XRPD consistent with Form 1.
List 4: XRPD peak listing for Form 4 (2Theta: most intense peaks are underlined)
Figure PCTCN2016099482-appb-000025
Form 4 can also be characterized by a subset of these peaks, for example the peaks at 7.0, 8.6, 19.3 and 20.9.
Form 5
A sample of Form 4 was dried under dry air flow for a day, giving a powder that exhibited the XRPD shown in Figure 6A. This material is referred to herein as Form 5. The DSC for Form 5 shows a sharp exotherm at about 204℃, and the sample begins turning black at about this temperature, indicating decomposition. TGA shows about 7％loss of mass between 45 ℃ and 160℃. Karl Fisher analysis shows a water content of 9.6％for Form 5, corresponding to a trihydrate, but the sample appears to lose mass at RH below about 30％； and at RH above 80％, it converts to Form 4 within a day.
Forms  1, 4 and 5 of Compound X thus appear to interconvert as relative humidity is varied, and it may be a mixture of these hydrated forms. Form 5 is a preferred form for handling at ambient temperatures around 25℃ during manufacture, because it crystallizes as a well-behaved solid that is more stable during storage and handling than other forms, provided suitable relative humidity of around 20-50％RH, preferably 30-40％, is maintained. Within these RH ranges, the material is primarily trihydrate and is suitably well-behaved and stable for handling and storage without special precautions.
Larger Scale Preparation of Form 5
Water (20 mL) and THF (40 mL) were mixed in a flask, and Compound X (10 g, ca. 91％pure by HPLC) was added with stirring at 25℃ to provide a clear yellow solution. A 20 mg sample of Form 5 (see above) was added as a seed, and the mixture was stirred for 50 mins. THF (140 mL) was then added slowly, over 1 hr and the mixture was stirred for 2 hr more. The suspension was filtered, and the wet cake was washed with cold (<5℃) water, then dried at 20-25℃ for 11 hrs at 100 mbar pressure, providing 6.6 g of Form 5 trihydrate that was 97.8％pure by HPLC. The sample produced the XRPD pattern shown in Figure 6B. It appears stable when stored at 25-50％relative humidity, preferably 30-40％RH； at lower or higher relative humidity, it may evolve to different hydrated states as described herein. Over-drying produces a form that decomposed at room temperature within a few hours, further demonstrating the stability advantage of hydrated forms.
List 5: XRPD peak listing for Form 5 (2Theta: most intense peaks are underlined)
Figure PCTCN2016099482-appb-000026
Figure PCTCN2016099482-appb-000027
Form 5 can also be characterized by a subset of these peaks, for example the peaks at 7.3, 9.3, and 27.8； and optionally by peaks at 7.3, 9.3, 19.9 and 27.8.
Form 5 (trihydrate) can alternatively be characterized by a single crystal X-ray structure that is monoclinic, space group P2 (1) , having unit cell dimensions
Figure PCTCN2016099482-appb-000028
Figure PCTCN2016099482-appb-000029
(α ＝ 90°； β ＝ 96.037°； γ ＝ 90°) ； and unit cell volume of 
Figure PCTCN2016099482-appb-000030
Data for this structure was collected at wavelength
Figure PCTCN2016099482-appb-000031
100 °K； theta range 3.99° to 68.44°； 47822 reflections collected. The single crystal structure confirms the presence of three water molecules per molecule of Compound X in the unit cell, with the water molecule located in channels.
Form 6
Compound X of Form 1 (1.2 g) was suspended in DMSO: water (25: 75 v/v ratio, 12 mL) and stirred at 20℃ for 3 days. A sample of the solid was collected and dried with filter paper. The product exhibited the XRPD pattern shown in Figure 7, and is referred to herein as Form 6. DSC and TGA are consistent with loss of solvent up to about 130℃ and again between 150℃ and 200℃, followed by degradation above 200℃.
List 6: XRPD peak listing for Form 6 (2Theta: most intense peaks are underlined)
Figure PCTCN2016099482-appb-000032
Figure PCTCN2016099482-appb-000033
Form 6 can also be characterized by a subset of these peaks, for example the peaks at 8.1, 9.2, and 12.8； and optionally by additional peaks at 21.2 and 24.7.
Form 7
Compound X of Form 6 made as described above was dried for a day under dry airflow. The resulting powder exhibited the XRPD pattern shown in Figure 8, and is referred to herein as Form 7. DSC shows a large exotherm starting about 134℃ and continuing to about 170℃. 1H NMR shows about 2 equivalents of DMSO present and some water (3.6％) . Karl Fisher titration confirms the presence of 3.6％water, corresponding to 1 equivalent. This form is thus a solvate.
List 7: XRPD peak listing for Form 7 (2Theta: most intense peaks are underlined)
Figure PCTCN2016099482-appb-000034
Figure PCTCN2016099482-appb-000035
Form 7 can also be characterized by a subset of these peaks, for example the peaks at 6.7, 7.3 and 20.3.
Form 8
Compound X of Form 1 (1.2 g) was suspended in methanol (12 mL) and stirred at 20℃ for 3 days. A sample of the solid was collected and produced the XRPD pattern shown in Figure 9 (without drying) , which is referred to herein as Form 8. When a sample of Form 8 was dried under dry air flow, the peaks broadened substantially but generally appear in about the same positions. TGA for the dried sample shows gradual loss of mass (about 4％) out to 140℃, and a sharper loss of mass beginning about 170℃. DSC shows a strong exotherm at about 172℃ that may be associated with degradation of the sample.
List 8: XRPD peak listing for Form 8 (2Theta: most intense peaks are underlined)
Figure PCTCN2016099482-appb-000036
Form 8 can also be characterized by a subset of these peaks, for example the peaks at 6.2, 21.8 and 25.9.
Form 9
Compound X of Form 3 was suspended in acetone and water at 25 ℃ to 40 ℃. The ratio of water to acetone was varied from 2: 98 to 10: 90. After equilibration for 24 hours, a low-crystallinity hetero-solvate form was obtained in each case. While the XRPD varied with the proportion of water to acetone, all samples produced XRPD spectra with broad humps rather than sharp peaks. Figure 10 shows the XRPD for a sample equilibrated in 10: 90 water/acetone at 40℃ for 24 hours, and the following table summarizes the XRPD data for this sample. This solid form is referred to herein as Form 9.
Figure PCTCN2016099482-appb-000037
Form 9 can be characterized by a subset of these peaks, for example the peaks identified in the table above as ‘strong’ relative intensity, e.g. peaks at 6.3 and 12.6 and optionally one or more of the peaks in the table having medium relative intensity, such as peaks at 22.1, 22.3, 23.1, 27.0 and 27.
Form 10
Compound X of Form 1 (anhydrate) was exposed to 43％relative humidity for one day or more. The crystalline product appears to be a sesquihydrate (Compound X- 1.5 H2O) based on water content determination. Note that Form 5, the trihydrate, under similar conditions would be stable, yet when starting with the anhydrate, it appears to equilibrate as a sequihdyrate under these conditions and remains in that form for at least 14 days when kept at the same relative humidity. This crystalline form produces the XRPD spectrum shown in Figure 11, and is referred to herein as Form 10. The table below summarizes the main peaks in the XRPD of this sample.
Figure PCTCN2016099482-appb-000038
Form 10 can be characterized by the XRPD peaks in the above table having medium to strong relative intensities, e.g. peaks at 6.6, 11.0, 13.3, 15.6, 16.5, 18.6, 22.2, 23.4 and 27.4. It can also be characterized by a subset of these peaks, for example the peaks having relative intensity of 40 or higher, e.g. peaks at 6.6, 11.0, 16.5, 22.2, and 23.4, or by a subset of at least 3 or 4 of these peaks.
Form 11
Compound X of Form 5, the trihydrate, was exposed to relative humidity of 22％for about 3 days to provide a crystalline solid characterized as a dihydrate (Compound X-2H2O) based on water content analysis. This material readily reverts to the trihydrate (Form 5) if exposed to relative humidity above about 40％. The dihydrate, referred to herein as Form 11, produced the XRPD spectrum shown in Figure 12: the main peaks in that XRPD spectrum are listed in the following table.
Figure PCTCN2016099482-appb-000039
Form 11 is characterized by the XRPD peaks in this table having relative intensities of 20 or higher, or alternatively those peaks having relative intensity of at least 25, e.g., peaks at 7.4, 9.7, 17.0, 19.5, 22.2, 26.3, 28.1, and 29.3, or a subset of 3, 4 or 5 of these peaks having relative intensity of at least 26 or at least 28 in the table.
Form 12
Compound X of Form 5 was exposed to air with a relative humidity of 65％for about 3 days, providing a crystalline material characterized as a tetra-hydrate based on water content analysis. This material readily reverts to the trihydrate (Form 5) if the relative humidity is reduced to about 40％. The tetrahydrate, referred to herein as Form 12, produced the XRPD spectrum shown in Figure 13: the main peaks in that XRPD spectrum are listed in the following table.
Figure PCTCN2016099482-appb-000040
Figure PCTCN2016099482-appb-000041
Form 12 can be characterized by XRPD peaks having a relative intensity of at least 40 in the table above, i.e. XRPD peaks at 7.3, 17.8, 19.0, 19.8, 20.4, 24.0, 24.7, 24.9, 27.2, 27.8 and 32.1. Alternatively, it can be characterized by a subset of at least 3, or at least 4, or at least 5 of these peaks. Form 12 can also be characterized by the XRPD peaks described as strong relative intensity in the table, i.e., peaks at 7.3, 19.0, 20.4, 24.0, 24.7, and 27.2.
Samples of the hydrates of Compound X, including Forms 5, 11 and 12 were shown to interconvert readily as the relative humidity was varied from about 22％to about 92％. Note that at 92％relative humidity, Compound X appears to be a mixture of a crystal form characterized as hexahydrate mixed with the tetrahydrate of Form 12. By comparison, the anhydrate (Form 1) preferentially converts to a sesquihydrate as the relative humidity is increased to 43％, and evolves to trihydrate and tetrahydrate at higher relative humidities.
Pharmaceutical Compositions of Compound X
Compound X (500 mg) and L-arginine (332.5 mg) are combined in a vial. Saccharose (crystalline, pyrogen-free sucrose: 1000 mg) is added along with water suitable for injection (8.00 mL) . The pH of the solution is adjusted, if necessary, using 1.0N HCl or 1.0N NaOH to arrive at a pH of 5.0±0.5, preferably a pH of 5.0±0.2. This provides a solution containing about 62.5 mg/mL of Compound X as an arginine salt. This solution can be filtered if necessary, and can be lyophilized to provide a white or off-white solid (lyophilizate) . The lyophilized solid can be reconstituted with sterile water or a pharmaceutically acceptable aqueous carrier such as isotonic saline or dextrose to provide a solution suitable for intravenous administration. The lyophilizate should be stored in a container that excludes light to protect the lyophilizate from photodegradation. This process can be scaled up or down to provide unit dosages for  storage and distribution, or bulk material that can be further processed as desired. For scale-up, temperature control is important: Compound X in solution should be maintained at a temperature below 10℃, preferably between 0℃ and 8℃, and more preferably between 2℃ and 8℃, prior to addition of arginine or other base, as the compound is subject to hydrolytic degradation in water in the absence of a base or outside the pH range of 4-6.
In one embodiment, a mixture according to the above example is prepared as described using the trihydrate (Form 5) of Compound X in an amount that contains about 500 mg of Compound X anhydrous, and is lyophilized in a vial that is then sealed for storage and distribution, preferably using a butyl rubber stopper (e.g., D777 stopper) , where the lyophilizate in each vial contains about 500 mg of Compound X. The vials of lyophilizate are stored at or below room temperature until use.
An alternative formulation suitable for IV injection contains Compound X (100 mg) and 0.5N Sodium bicarbonate (0.75 mL) , and pH adjuster if necessary (1 N NaOH or 1 N HCl as needed) to bring the pH to about 5.5 (between pH 5 and pH 6) , plus an amount of water for injection sufficient to achieve a final concentration of 100 mg/ml.
Stability of Compound X
Compound X is stable in solid form, but salts of Compound X are more stable in solution than the free acid； thus it became important to identify suitable pharmaceutically acceptable salts to use for administration. Salts of Compound X were prepared by adding a base (1.0 or 2.0 equiv. ) to Compound X in water, and lyophilizing the solution. The solids thus obtained appear to be amorphous by XRPD. In this manner, formation of salts of Compound X were attempted with sodium hydroxide, (L) -lysine, (L) -arginine, calcium hydroxide, meglumine, and magnesium hydroxide. The sodium salts and the arginine salts were found to be particularly stable and thus desirable as forms for administration in aqueous media typically used for intravenous injections and infusions.
Samples of the disodium salt and the di- (L) -arginine salt as solids were subjected to stability testing at 25℃ and 40℃. The sample of sodium salt was 97.2％pure by HPLC  initially, and after 6 weeks at 25℃, it was still 96.2％pure. The same material held at 40℃ was 94.8％pure after 3 weeks, and 93.6％pure after 6 weeks. Significant impurities that appear or increase during the study appear at relative retention times (RRT) 0.34 and 1.11 (with Compound X defined as RRT ＝ 1) .
The arginine salt was 97.3％pure by HPLC initially, and was 96.3％pure after 6 weeks at 25℃. At 40℃, its purity dropped to 95.1％after 3 weeks and 94.2％after 6 weeks. Significant impurities that appear or increase during this study appear at relative retention times (RRT) 1.09, 1.11 and 1.13 (with Compound X defined as RRT ＝ 1) . The HPLC traces for the samples from these stability studies after 6 weeks at 25℃ and 40℃ respectively are shown in Figures 10 and 11. The lower trace in each Figure is a sample used to measure the limit of quantitation (LOQ) ； the next trace above that represents the sample of Compound X used for salt formation； the next trace above that one is for the arginine salt after 6 weeks； and the next (top) trace is for the sodium salt after 6 weeks.
HPLC Conditions for the stability studies (Figures 10 and 11) :
Agilent 1290 system with UV detector at 260 nm
Acquity HSS T3 column, 100mm x 2.1mm ID； 1.8 μm particle size (supplied by Waters)
Column temp: 40℃
Mobile phases
A: 0.05％TFA in water
B: 0.05％TFA in methanol
Flow rate: 0.45 mL/min
Gradient (A/B ratio) : 97: 3 for 8 minutes； 75: 25 for 3 minutes； 0: 100 for 1 minute
Compound X was also found to degrade photochemically； thus Compound X should be stored in dark or opaque containers for best shelf life. In one embodiment of the invention, Compound X is packaged in a container that substantially reduces exposure to light, preferably in an atmosphere at a relative humidity of 25-50％humidity and more preferably at a relative humidity of 30-40％or 30-45％.
Biological Activity
Bacterial Screens and Cultures
Bacterial isolates were cultivated from -70℃ frozen stocks by two consecutive overnight passages at 35℃ in ambient air on 5％blood agar (Remel, Lenexa, Kans. ) . Quality control and P. aeruginosa ATCC 27853) is from the American Type Culture Collection (ATCC； Rockville, Md. ) and PAO1 was received from Dr. K. Poole.
Construction of Escherichia coli isogenic strains Strains NB27273-CDY0026 (parent) , NB27273-CDY0033 (KPC2) and NB27273-CDY0030 (SHV12)
Strain NB27273 (BW25113 pspB: : Kmr) was obtained from the Keio transposon insertion collection. The strain has the pspB gene replaced by a kanamycin resistance marker (BW25113 pspB: : Kmr) . This strain was cured of the transposon in pspB via FLP recombinase using published methodology. The resulting strain, BW25113 pspB, was used as a host for multicopy vectors expressing key β-lactamases. Multicopy plasmids directing constitutive expression of β-lactamases were established as follows: Synthetic, codon optimized genes encoding E. coli KPC2 and SHV12-lactamases were made by DNA2.0 (Palo Alto, CA) . Each of the synthetic fragments were designed to contain NotI and NcoI restriction sites at their termini, allowing ligation into a NotI/NcoI digested pET28a (+) derivative for protein expression. The inserts in these vectors served as template DNA for PCR amplification of the gene encoding KPC2 and SHV12, using primer pairs E225 (tcgcCTCGAGgcgactgcgctgacgaatttgg) (SEQ ID NO: 1) and E202 (aatcGAATTCttactgaccattaacgcccaagc) (SEQ ID NO: 2) and E227 (tcgcCTCGAGgcgagcccgcaaccgctgga) (SEQ ID NO: 3) and E204 (aatcGAATTCttaacgctgccagtgctcaatc) (SEQ ID NO: 4) , respectively. The codon optimized nucleotide sequences and relevant primer recognition information is shown below:
SHV12
Figure PCTCN2016099482-appb-000042
Figure PCTCN2016099482-appb-000043
KPC2
Figure PCTCN2016099482-appb-000044
UNDERLINED ＝ DNA ENCODING BL
The PCR products were then digested with XhoI and EcoRI and ligated into similarly digested plasmid pAH63-pstS (BlaP) . Plasmid pAH63-pstS (BlaP) is a derivative of plasmid pAH63 (J Bacteriol: 183 (21) : 6384–6393) made by cloning the TEM-1 (bla) promoter and signal peptide encoding region from plasmid pBAD (J Bacteriol. 1995 Jul. 177 (14) : 4121-30) into plasmid pAH63. This fragment was PCR amplified from pBAD using primer pair E192 (ttcaCTGCAGtgaacgttgcgaagcaacggC) (SEQ ID NO: 13) and E194 (TCGAggatcctcgagagcaaaaacaggaaggcaaaatgccg) (SEQ ID NO: 14) , digested with PstI and BamHI and inserted into similarly digested plasmid pAH63. Therefore, expression of β-lactamases from pAH63-pstS (BlaP) based constructs is constitutive and the signal sequence is provided to direct these proteins to the periplasm. Plasmid pAH63 based vectors are used for insertion into the genome in single copy, however, to provide higher expression levels to allow more sensitive detection of the susceptibility of compounds to the β-lactamases, the expression inserts contained in these vectors were moved to the replicative multicopy vector pBAD-Kan (J Bacteriol. 1995 Jul. 177 (14) : 4121-30) . To accomplish this, the inserts encompassing the β-lactamase genes, with the associated TEM promoter and signal sequences, were PCR amplified from their corresponding vectors using primer E269 (ccgTCTAGAcggatggcctttttgcgtttc) (SEQ ID NO: 15) and E202 (aatcGAATTCttactgaccattaacgcccaagc) (SEQ ID NO: 16) for the KPC2 construct and E204 (aatcGAATTCttaacgctgccagtgctcaatc) (SEQ ID NO: 17) for the SHV12 construct. These fragments were then digested with XbaI and EcoRI, and each was inserted into pBAD18-kan that had been digested with the same enzymes to generate a pair of multicopy vectors expressing KPC2 and SHV12 respectively. These vectors were transformed into BW25113 pspB to generate strains NB27273-CDY0033 (expressing KPC2) and NB27273-CDY0030 (expressing SHV12) . The pBAD18-kan vector also contains the TEM promoter region and signal sequence, (but lacks any intact β-lactamase genes) and was transformed into BW25113 pspB using standard protocols to generate the control strain NB27273-CDY0026. Expression of the β-lactamases was confirmed by verifying decreased susceptibility to example test antibiotics that are known substrates of KPC2 or SHV12.
Susceptibility Testing
Minimal Inhibitory Concentrations (MICs) were determined by the broth microdilution method in accordance with Clinical and Laboratories Institute (CLSI) guidelines. In brief, fresh overnight bacterial cultures were suspended in sterile saline, and adjusted to a 0.5  McFarland turbidity standard. Bacterial suspensions were then diluted in cation adjusted Mueller-Hinton Broth (MHB II； BBL) to yield a final inoculum of approximately 5x105 colony-forming units (CFU) /mL. A master plate of antibiotics was prepared at a concentration equivalent to hundred-fold the highest desired final concentration in 100％dimethyl sulfoxide (DMSO) . The master antibiotic plate was then diluted by serial twofold dilution with a multichannel pipette. The resulting dilution series of compounds were diluted 1: 10 with sterile water leading to a 10％DMSO final concentration. A volume of 10 μL of the drug dilution series was transferred to 96-well assay plates. Assay plates were inoculated with 90 μL of bacterial suspensions and incubated at 35-37℃ for 20 hrs. The assay plates were read using a microtiter plate reader (Molecular Devices) at 600nm as well as by visual observation with a reading mirror. The lowest concentration of the compound that prevented visible growth was recorded as the MIC. Performance of the assay was monitored by testing aztreonam against laboratory quality control strains in accordance with guidelines of the CLSI.
Reference compounds: for comparison, the following known monobactam compounds are used herein:
Reference compound 1: Aztreonam
Figure PCTCN2016099482-appb-000045
Reference compound 2: Carumonam
Figure PCTCN2016099482-appb-000046
Reference compound 3: BAL30072
Figure PCTCN2016099482-appb-000047
Reference compound 4: Aicuris WO2013110643
Figure PCTCN2016099482-appb-000048
Table A: Minimum Inhibitory Concentrations (MIC) against isogenic strains of E. coli, carrying various resistance determinants.
Figure PCTCN2016099482-appb-000049
Strain 1: E. coli NB27273-CDY0026 (parent)
Strain 2: E. coli NB27273-CDY0033 (KPC2)
Strain 3: E. coli NB27273-CDY0030 (SHV12)
The data in Table A show that Compound X has good antibacterial potency against E. coli, including strains that show strong resistance to several known monobactam and sulfactam antibiotics.
Additional activity data for Compound X is provided in the following table. Compound X was tested on E. coli strain 25922 and an E. coli containing KPC-2 (Strain 2 above, which is a known carbapenemase from Klebsiella pneumoniae) , and exhibited these Inhibitory Concentrations (MIC) , in mg/mL.
Figure PCTCN2016099482-appb-000050

Claims (30)

  1. An (L) -arginine salt of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4-( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid.
  2. A sodium salt of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid.
  3. A hydrated solid form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid.
  4. The hydrated solid form according to claim 3, which consists mainly of a trihydrate of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid.
  5. A method to prepare the hydrated solid form according to claim 4, which comprises contacting 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4-( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid with an atmosphere having relative humidity between 25％ and 50％ at a temperature between 20℃ and 30℃.
  6. A pharmaceutical composition comprising a compound according to any one of claims 1-4 and at least one pharmaceutically acceptable carrier or excipient.
  7. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4-( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 1) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 6.6. 13.4, and 18.8.
  8. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4-( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 2) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 7.5, 19.3, and 20.0.
  9. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4-( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 3) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 7.3, 18.9, and 21.2.
  10. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4-( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 4) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 7.0, 8.6, 19.3 and 20.9.
  11. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4-( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 5) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 7.3, 9.3, and 27.8
  12. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4-( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 6) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 8.1, 9.2, and 12.8； and optionally by additional peaks at 21.2 and 24.7.
  13. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4-( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 7) which exhibits at least the following  characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 6.7, 7.3 and 20.3.
  14. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4-( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 8) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 6.2, 21.8 and 25.9.
  15. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4-( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 9) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 6.3, 12.6, and 22.3； and optionally by  one or more additional peaks selected from 22.1, 23.1, 27.0 and 27.5.
  16. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4-( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 10) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 6.6, 11.0, and 16.5； and optionally by one or more additional peaks selected from 22.2 and 23.4.
  17. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4-( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 11) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 7.4, 9.7, and 29.3； and optionally by one or more additional peaks selected from peaks at 17.0, 19.5, 22.2, 26.3 and 28.1.
  18. A crystalline form of 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4-( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid (Form 12) which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2θ) : 19.0,  20.4, and 24.0； and optionally by one or more additional peaks selected from peaks at 7.3, 24.7, and 27.2.
  19. A pharmaceutical composition comprising 1- ( ( (Z) - (1- (2-aminothiazol-4-yl) -2-oxo-2- ( ( (3S, 4R) -2-oxo-4- ( (2-oxooxazolidin-3-yl) methyl) -1-sulfoazetidin-3-yl) amino) ethylidene) amino) oxy) cyclopropanecarboxylic acid and arginine.
  20. The pharmaceutical composition of claim 19, which further comprises a pharmaceutically acceptable carrier.
  21. The pharmaceutical composition of claim 20, wherein the carrier is aqueous.
  22. The pharmaceutical composition of claim 21, which is at a pH of about 5.0.
  23. The pharmaceutical composition of claim 21 or 22, which further comprises at least one excipient selected from sucrose, fructose, trehalose, mannitol, and lactose.
  24. A compound according to any one of claims 1-4, or a crystalline form thereof according to any one of claims 7 to 18, for use in therapy.
  25. The compound of claim 24, wherein the therapy is the treatment of a Gram-negative bacterial infection.
  26. The compound according to claim 24, wherein the bacterium causing the Gram-negative bacterial infection is selected from Citrobacter, Enterobacter, Eschirichia, Haemophilus, Klebsiella, Morganella, Moraxella, Pseudomonas, Proteus, Salmonella, Serratia, Shigella, and Neisseria bacteria.
  27. Use of a compound according to any one of claims 1 to 4, or a crystalline form thereof according to any one of claims 7 to 18, in the manufacture of a medicament for the treatment of a Gram-negative bacterial infection.
  28. Use, according to claim 27, wherein the bacterium causing the Gram-negative bacterial infection is a species selected from Citrobacter, Enterobacter, Eschirichia, Haemophilus, Klebsiella, Morganella, Moraxella, Pseudomonas, Proteus, Salmonella, Serratia, Shigella, and Neisseria bacteria.
  29. A method of treatment for a Gram-negative infection, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 4, or a crystalline form according to any one of claims 7 to 18, or a pharmaceutical composition according to any one of claims 19-23.
  30. The method of claim 29, wherein the bacterium causing the Gram-negative bacterial infection is a species selected from Citrobacter, Enterobacter, Eschirichia, Haemophilus, Klebsiella, Morganella, Moraxella, Pseudomonas, Proteus, Salmonella, Serratia, Shigella, or Neisseria bacteria.
PCT/CN2016/099482 2015-09-23 2016-09-20 Salts and solid forms of monobactam antibiotic WO2017050218A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
BR112018005805-0A BR112018005805B1 (en) 2015-09-23 2016-09-20 SALT AND SOLID FORMS OF A MONOBACTAM ANTIBIOTIC
RU2018114480A RU2754180C2 (en) 2015-09-23 2016-09-20 Salts and solid forms of monobactam antibiotic
MA42946A MA42946B1 (en) 2015-09-23 2016-09-20 Salts and solid forms of a monobactam antibiotic
ES16848099T ES2817537T3 (en) 2015-09-23 2016-09-20 Salts and solid forms of a monobactam antibiotic
EA201890771A EA037569B1 (en) 2015-09-23 2016-09-20 Salts of monobactam antibiotic and use thereof
US15/762,724 US10919887B2 (en) 2015-09-23 2016-09-20 Salts and solid forms of a monobactam antibiotic
KR1020187011354A KR20180054816A (en) 2015-09-23 2016-09-20 Salts and solid forms of monosaccharide antibiotics
EP16848099.4A EP3353175B1 (en) 2015-09-23 2016-09-20 Salts and solid forms of a monobactam antibiotic
CA2999794A CA2999794C (en) 2015-09-23 2016-09-20 Salts and solid forms of monobactam antibiotic
JP2018515607A JP6837480B2 (en) 2015-09-23 2016-09-20 Monobactam antibiotic salt and solid form
DK16848099.4T DK3353175T3 (en) 2015-09-23 2016-09-20 Salts and solid forms of a monobactam antibiotic
MX2018003592A MX2018003592A (en) 2015-09-23 2016-09-20 Salts and solid forms of monobactam antibiotic.
CN201680055680.4A CN108137573B (en) 2015-09-23 2016-09-20 Salts and solid forms of monocyclolactam antibiotics
LTEP16848099.4T LT3353175T (en) 2015-09-23 2016-09-20 Salts and solid forms of a monobactam antibiotic
AU2016327264A AU2016327264B2 (en) 2015-09-23 2016-09-20 Salts and solid forms of monobactam antibiotic
SI201630906T SI3353175T1 (en) 2015-09-23 2016-09-20 Salts and solid forms of a monobactam antibiotic
RS20201038A RS60805B1 (en) 2015-09-23 2016-09-20 Salts and solid forms of a monobactam antibiotic
IL258254A IL258254B (en) 2015-09-23 2018-03-20 Salts and solid forms of monobactam antibiotic
PH12018500653A PH12018500653A1 (en) 2015-09-23 2018-03-23 Salts and solid forms of monobactam antibiotic
HK18116415.3A HK1257271A1 (en) 2015-09-23 2018-12-21 Salts and solid forms of monobactam antibiotic
HRP20201423TT HRP20201423T1 (en) 2015-09-23 2020-09-07 Salts and solid forms of a monobactam antibiotic
CY20201100840T CY1123509T1 (en) 2015-09-23 2020-09-07 SALTS AND SOLID FORMS OF AN ANTIBIOTIC MONOBACTAM

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562222430P 2015-09-23 2015-09-23
US62/222,430 2015-09-23

Publications (1)

Publication Number Publication Date
WO2017050218A1 true WO2017050218A1 (en) 2017-03-30

Family

ID=58385723

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/099482 WO2017050218A1 (en) 2015-09-23 2016-09-20 Salts and solid forms of monobactam antibiotic

Country Status (25)

Country Link
US (1) US10919887B2 (en)
EP (1) EP3353175B1 (en)
JP (1) JP6837480B2 (en)
KR (1) KR20180054816A (en)
CN (1) CN108137573B (en)
AU (1) AU2016327264B2 (en)
CA (1) CA2999794C (en)
CL (2) CL2018000745A1 (en)
CY (1) CY1123509T1 (en)
DK (1) DK3353175T3 (en)
EA (2) EA202092620A1 (en)
ES (1) ES2817537T3 (en)
HK (1) HK1257271A1 (en)
HR (1) HRP20201423T1 (en)
HU (1) HUE050849T2 (en)
IL (1) IL258254B (en)
LT (1) LT3353175T (en)
MA (1) MA42946B1 (en)
MX (1) MX2018003592A (en)
PH (1) PH12018500653A1 (en)
PT (1) PT3353175T (en)
RS (1) RS60805B1 (en)
RU (1) RU2754180C2 (en)
SI (1) SI3353175T1 (en)
WO (1) WO2017050218A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019092180A1 (en) * 2017-11-10 2019-05-16 Novartis Ag Administration of monobactam for the treatment of urinary tract infection
WO2019144969A1 (en) 2018-01-29 2019-08-01 南京明德新药研发股份有限公司 Monocyclic β-lactam compound for treating bacterial infection
CN111094281A (en) * 2017-08-02 2020-05-01 诺华股份有限公司 Chemical process for the preparation of monobactam antibiotics and intermediates thereof
WO2020125670A1 (en) 2018-12-18 2020-06-25 南京明德新药研发有限公司 APPLICATION OF MONOCYCLIC β-LACTAM COMPOUND IN PHARMACY
JP2020531621A (en) * 2017-08-16 2020-11-05 エルジー・ケム・リミテッド A method of changing the color of a medium using a white pigment containing a ZIF-based powder, a polymer resin film, and a white pigment.
WO2021121387A1 (en) 2019-12-19 2021-06-24 南京明德新药研发有限公司 Application of compound in drug preparation
WO2021244199A1 (en) 2020-06-02 2021-12-09 中国医学科学院医药生物技术研究所 β-LACTAM COMPOUND, USE THEREOF AND PREPARATION METHOD THEREFOR
WO2022027439A1 (en) * 2020-08-06 2022-02-10 Ningxia Academy Of Agriculture And Forestry Sciences β-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS
WO2022185241A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Process for manufacturing a monobactam antibiotic
WO2022185240A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Formulation of a monobactam antibiotic
EP4378941A4 (en) * 2022-10-12 2024-07-24 Suzhou Erye Pharmaceutical Co Salt form of compound having substituted sulfonylurea ring and crystal form thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7446424B2 (en) * 2019-11-22 2024-03-08 スージョウ アーイェ ファーマシューティカル カンパニー リミテッド Sulfonylurea ring-substituted monocyclic β-lactam antibiotics

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0093376A2 (en) * 1982-04-30 1983-11-09 Takeda Chemical Industries, Ltd. 1-Sulfo-2-azetidinone derivatives, their production and use
WO2010070523A1 (en) * 2008-12-19 2010-06-24 Pfizer Inc. Monocarbams
WO2012073138A1 (en) * 2010-11-29 2012-06-07 Pfizer Inc. Monobactams
WO2013110643A1 (en) * 2012-01-24 2013-08-01 Aicuris Gmbh & Co. Kg Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents
WO2015148379A1 (en) * 2014-03-24 2015-10-01 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ205240A (en) 1980-02-07 1984-07-31 Squibb & Sons Inc Sulphonamide derivatives,being starting materials for producing beta-lactams
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
EP0048953B1 (en) 1980-09-29 1988-03-09 E.R. Squibb &amp; Sons, Inc. Beta-lactam antibiotics
WO1982001873A1 (en) 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4782147A (en) 1980-12-05 1988-11-01 Takeda Chemical Industries, Ltd. 1-sulfo-2-oxoazetidine derivatives and their production
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
IL67451A (en) 1981-12-25 1987-10-20 Takeda Chemical Industries Ltd 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them
SU1195908A3 (en) 1982-05-31 1985-11-30 Баниу Фармасьютикал Ко.,Лтд.(Фирма) Method of producing 2-oxo-1-azetidinesulfoacid derivatives or their salts with alkali metals
DE3377061D1 (en) 1982-06-03 1988-07-21 Hoffmann La Roche Process for the preparation of 1-sulfo-2-oxoazetidine derivatives
JPS6153282A (en) 1984-08-22 1986-03-17 Banyu Pharmaceut Co Ltd Monocyclic beta-lactam derivative
JPS6153283A (en) 1984-08-24 1986-03-17 Banyu Pharmaceut Co Ltd 2-oxo-1-azetidinesulfonic acid derivative
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
EP2341053B1 (en) 2008-10-31 2016-01-13 Shionogi&Co., Ltd. Cephalosporin having catechol group
CN103044416A (en) 2012-12-17 2013-04-17 浙江华方药业有限责任公司 Synthetic method of Carumonam sodium
WO2015103583A1 (en) 2014-01-06 2015-07-09 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0093376A2 (en) * 1982-04-30 1983-11-09 Takeda Chemical Industries, Ltd. 1-Sulfo-2-azetidinone derivatives, their production and use
WO2010070523A1 (en) * 2008-12-19 2010-06-24 Pfizer Inc. Monocarbams
WO2012073138A1 (en) * 2010-11-29 2012-06-07 Pfizer Inc. Monobactams
WO2013110643A1 (en) * 2012-01-24 2013-08-01 Aicuris Gmbh & Co. Kg Amidine substituted beta - lactam compounds, their preparation and use as antibacterial agents
WO2015148379A1 (en) * 2014-03-24 2015-10-01 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEAL G. ANDERSON: "of Pharmaceutical Salts; Properties, Selection and Use", VERLAG HELVETICA CHIMICA ACTA

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7235718B2 (en) 2017-08-02 2023-03-08 ノバルティス アーゲー Chemical methods for producing monobactam antibiotics and their intermediates
CN111094281A (en) * 2017-08-02 2020-05-01 诺华股份有限公司 Chemical process for the preparation of monobactam antibiotics and intermediates thereof
US11414411B2 (en) 2017-08-02 2022-08-16 Novartis Ag Chemical process for manufacturing monobactam antibiotic and intermediates thereof
JP2020529398A (en) * 2017-08-02 2020-10-08 ノバルティス アーゲー Chemical methods for producing monobactam antibiotics and their intermediates
CN111094281B (en) * 2017-08-02 2023-08-29 诺华股份有限公司 Chemical process for preparing monolactam antibiotics and intermediates thereof
JP7120516B2 (en) 2017-08-16 2022-08-17 エルジー・ケム・リミテッド White pigment containing ZIF-based powder, polymeric resin film and method for changing the color of a medium using white pigment
JP2020531621A (en) * 2017-08-16 2020-11-05 エルジー・ケム・リミテッド A method of changing the color of a medium using a white pigment containing a ZIF-based powder, a polymer resin film, and a white pigment.
WO2019092180A1 (en) * 2017-11-10 2019-05-16 Novartis Ag Administration of monobactam for the treatment of urinary tract infection
CN111511737A (en) * 2018-01-29 2020-08-07 南京明德新药研发有限公司 Monocyclic β -lactam compounds for the treatment of bacterial infections
JP2021512866A (en) * 2018-01-29 2021-05-20 メッドシャイン ディスカバリー インコーポレイテッド Monocyclic β-lactam compounds for treating bacterial infections
CN111511737B (en) * 2018-01-29 2022-10-18 南京明德新药研发有限公司 Monocyclic beta-lactam compounds for the treatment of bacterial infections
JP7280273B2 (en) 2018-01-29 2023-05-23 メッドシャイン ディスカバリー インコーポレイテッド Monocyclic β-Lactam Compounds for Treating Bacterial Infections
WO2019144969A1 (en) 2018-01-29 2019-08-01 南京明德新药研发股份有限公司 Monocyclic β-lactam compound for treating bacterial infection
US11459323B2 (en) 2018-01-29 2022-10-04 Medshine Discovery Inc. Monocyclic β-lactam compound for treating bacterial infection
WO2020125670A1 (en) 2018-12-18 2020-06-25 南京明德新药研发有限公司 APPLICATION OF MONOCYCLIC β-LACTAM COMPOUND IN PHARMACY
WO2021121387A1 (en) 2019-12-19 2021-06-24 南京明德新药研发有限公司 Application of compound in drug preparation
WO2021244199A1 (en) 2020-06-02 2021-12-09 中国医学科学院医药生物技术研究所 β-LACTAM COMPOUND, USE THEREOF AND PREPARATION METHOD THEREFOR
WO2022027439A1 (en) * 2020-08-06 2022-02-10 Ningxia Academy Of Agriculture And Forestry Sciences β-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS
CN114728953A (en) * 2020-08-06 2022-07-08 宁夏农林科学院 Beta-lactam compounds, process for their preparation and their use as antibiotics
CN114728953B (en) * 2020-08-06 2024-04-09 宁夏农林科学院 Beta-lactams, process for their preparation and their use as antibiotics
WO2022185240A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Formulation of a monobactam antibiotic
WO2022185241A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Process for manufacturing a monobactam antibiotic
EP4378941A4 (en) * 2022-10-12 2024-07-24 Suzhou Erye Pharmaceutical Co Salt form of compound having substituted sulfonylurea ring and crystal form thereof

Also Published As

Publication number Publication date
US20180273522A1 (en) 2018-09-27
EA037569B1 (en) 2021-04-15
CN108137573A (en) 2018-06-08
EP3353175B1 (en) 2020-08-12
AU2016327264B2 (en) 2019-06-27
IL258254B (en) 2021-02-28
CL2018000745A1 (en) 2018-06-22
PH12018500653A1 (en) 2018-10-01
MX2018003592A (en) 2018-06-18
JP2018528241A (en) 2018-09-27
ES2817537T3 (en) 2021-04-07
DK3353175T3 (en) 2020-09-14
EA201890771A1 (en) 2018-09-28
HK1257271A1 (en) 2019-10-18
JP6837480B2 (en) 2021-03-03
RU2754180C2 (en) 2021-08-30
BR112018005805A2 (en) 2018-10-16
HRP20201423T1 (en) 2020-12-11
PT3353175T (en) 2020-09-10
AU2016327264A1 (en) 2018-05-10
LT3353175T (en) 2020-10-12
EP3353175A1 (en) 2018-08-01
RU2018114480A (en) 2019-10-23
CA2999794A1 (en) 2017-03-30
EP3353175A4 (en) 2019-06-26
CN108137573B (en) 2021-06-11
CY1123509T1 (en) 2022-03-24
MA42946A (en) 2018-08-01
SI3353175T1 (en) 2020-11-30
EA202092620A1 (en) 2021-06-30
HUE050849T2 (en) 2021-01-28
RU2018114480A3 (en) 2020-06-09
IL258254A (en) 2018-05-31
RS60805B1 (en) 2020-10-30
CL2019003324A1 (en) 2020-04-17
US10919887B2 (en) 2021-02-16
CA2999794C (en) 2023-08-15
KR20180054816A (en) 2018-05-24
MA42946B1 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
AU2016327264B2 (en) Salts and solid forms of monobactam antibiotic
KR102671585B1 (en) Macrocyclic broad-spectrum antibiotic
CN108137574B (en) Hydroxyalkyl thiadiazole derivatives
ES2928152T3 (en) Crystalline form of a beta-lactamase inhibitor and method of preparation thereof
BR112018005805B1 (en) SALT AND SOLID FORMS OF A MONOBACTAM ANTIBIOTIC
CN109096309B (en) One kind 43/4His acridine compound of head spore and its pharmaceutical composition
US20190309017A1 (en) Glutaminase inhibitors
CN109705015A (en) Histon deacetylase (HDAC) inhibitor and preparation method thereof and purposes
WO2018192445A1 (en) Polycyclic compound having parp inhibition activity, and uses thereof
CN109096308A (en) 1/4 water cefmenoxime hydrochloride compound of one kind and its pharmaceutical composition
CN109134504A (en) 1/2 water cefmenoxime hydrochloride compound of one kind and its drug combination preparation
CN108948079A (en) A kind of specially azoles amine di-ammonium salts and crystal form and preparation method

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16848099

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 258254

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/003592

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2999794

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12018500653

Country of ref document: PH

Ref document number: 2018515607

Country of ref document: JP

Ref document number: 15762724

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018005805

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 201890771

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20187011354

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2016848099

Country of ref document: EP

Ref document number: 2018114480

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2016327264

Country of ref document: AU

Date of ref document: 20160920

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112018005805

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180323